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CHAPTER I 
 
INTRODUCTION 
Diabetic retinopathy background 
Diabetes mellitus is a chronic, systemic disease characterized by several 
metabolic changes including abnormal insulin signaling, altered blood lipid levels, and 
elevated blood glucose. Diabetes mellitus occurs in two primary types. Type 1, or 
insulin-dependent, diabetes is an auto-immune disease that specifically targets the 
insulin-producing β-cell of the pancreatic islet. Type 2 diabetes, often referred to as 
adult-onset or non-insulin-dependent diabetes, is most commonly associated with 
obesity and is characterized by peripheral resistance to insulin. Type 2 diabetes 
accounts for about 90% of all diabetes cases. As of 2012, an estimated 29.1 million 
Americans have diabetes, costing an estimated 245 billion dollars in medical 
expenses.1 
Secondary to diabetes, various microvascular complications are prevalent, 
including diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy (DR). 
Diabetic retinopathy is the leading cause of blindness in working aged Americans.2 Of 
the estimated 285 million diabetics worldwide, one third show signs of DR.3 The 
pathology of DR presents in two clinically distinct forms referred to as non-proliferative 
(NPDR), the early stage characterized by fundus abnormalities including 
microaneurysms, hemorrhages and vasoregression, and proliferative (PDR), the later 
stage characterized by pre-retinal neovascularization. Additionally, diabetic macular 
edema (DME), characterized by fluid accumulation in extravascular parenchyma, is the 
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leading cause of vision loss associated with diabetes, largely due to its high prevalence 
in patients with type 2 diabetes.3,4 
Various risk factors are associated with DR. Of all identified risk factors, the time 
from diagnosis is the most highly correlated with retinopathy progression.5 For example, 
in The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), which used a 
type 1 diabetes patient population, prevalence of any retinopathy was 25% at 5 years 
and 80% at 15 years; PDR prevalence was 0% at 3 years and 25% by 15 years with 
diabetes.5,6 Several additional clinical studies worldwide have supported time from 
diagnosis as the most prominent risk factor for DR.7-10 Furthermore, the mean age of 
initial diagnosis, particularly of type 2 diabetes, continues to decrease.11 Thus, the rates 
of vision-threatening pathology from DR can be expected to increase.  
Another prominent risk factor for DR pathogenesis is control of blood glucose. In 
the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective 
Diabetes Study (UKPDS), intensive blood glucose control, which is defined as 3 or more 
daily injections of insulin, was associated with a slowed progression of DR.12,13 A meta-
analysis of worldwide diabetic retinopathy studies confirmed elevated HbA1c as a major 
risk factor for DR progression.3 These studies concluded that early and tight blood 
glucose control is important for limiting DR progression and the need for ophthalmic 
treatment. Despite the benefits of tight blood glucose control, intensive treatment 
strategies carry the risk of potentially fatal hypoglycemia.14 
Dyslipidemia, defined by elevation of either serum cholesterol or triglycerides, 
has more recently been accepted as a DR risk factor. The Early Treatment Diabetic 
Retinopathy Study (ETDRS) initially identified a positive correlation between diabetic 
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retinopathy pathology and serum lipid levels,15 and meta-analysis from 35 clinical 
studies established a relationship between high serum cholesterol and prevalence of 
DME.7 Supporting these correlations, lipid-lowering therapeutic strategies have been 
observed to slow the progression of DR. In the Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) studies, the lipid-lowering drug, fenofibrate, delayed retinopathy progression 
and the need for laser treatment, a common therapeutic strategy for DR.16,17 Notably, 
these effects were observed independent of glycemic control. 
Currently, there are two major therapeutic strategies for treatment of diabetic 
retinopathy. The first therapeutic strategy, developed in 1985, is laser photocoagulation 
for the treatment of DME or PDR.18 Laser photocoagulation is applied either focally to 
cauterize leaky vessels or in a panretinal grid to ablate oxygen utilizing cells, thus 
increasing oxygenation in the perfused portions of the retina and reducing growth factor 
production.19 The goal of laser application is to protect high acuity central vision by 
delaying disease advancement, but this comes at the expense of the peripheral retina. 
Consequently, this treatment is successful at slowing the progression of 
neovascularization and preserving vision in the late stages of the disease, but it also 
kills the post-mitotic neuronal cells of the retina. Thus, patients lose peripheral and night 
vision, and in some cases, photocoagulation causes eventual worsening of macular 
edema.20  
Despite the efficacy of laser photocoagulation, the invasive nature and negative 
side effects of laser treatments provides a strong impetus to develop additional 
therapies for DR. Anti-vascular endothelial growth factor (anti-VEGF) is an additional 
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therapeutic strategy that was more recently been approved for DME and, in some 
cases, PDR. VEGF is a potent angiogenic and permeability factor that is elevated in the 
vitreous of patients with DR.21,22 Anti-VEGF therapy was quickly approved for clinical 
use in DR patients because it was already used as a therapy for age-related macular 
degeneration to treat choroidal neovascularization. Several products in the clinic 
prevent or limit VEGF signaling. These include targeted antibodies against VEGF, such 
as ranibizumab (Lucentis) and bevacizumab (Avastin), the RNA aptamer pegaptanib 
(Macugen), which binds the VEGF-A165 isomer, and the soluble VEGF receptor 
aptamer, aflibercept (Eylea). These anti-VEGF therapies are all delivered intravitreally, 
thereby maximizing retinal efficacy and limiting systemic effects. While these therapies 
are predominantly used in diabetics for the treatment of DME, they have more recently 
been used for treatment of PDR in conjunction with panretinal photocoagulation, which 
remains the proven standard of care. 
These VEGF-directed therapies have demonstrated great promise in the clinic. 
For instance, 61.4% of DR patients treated with bevacizumab had complete regression 
of neovascularization.23 While the observed efficacy is promising, there are a number of 
problems associated with anti-VEGF therapies. First, they require repeat injections 
every few months, which makes patient compliance a challenge. Additionally, these 
repeated intravitreal injections increase the likelihood of endophthalmitis, an 
inflammatory and potentially blinding infection to the eye that can occur following globe 
puncture during injection.24 The incidence of endophthalmitis in response to anti-VEGF, 
is low, ranging from 0.009-1.9%,25,26 however, intravitreal injections are repeatedly 
administered, increasing the likelihood of infection. Lastly, VEGF receptors are 
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expressed in retinal neuronal and glial cells, and VEGF activation of these receptors is 
involved in their survival.27,28 Hence, while anti-VEGF therapies are successful in 
limiting DME, they may cause long-term neuronal problems when administered 
chronically for many years.29,30 It is important to note that anti-VEGF therapies are not 
efficacious in all patients.30 Therefore, there remains a need to develop novel 
therapeutic strategies that are less invasive, more sustainable, and carry fewer 
complications. Moreover, anti-VEGF and laser photocoagulation are directed at late 
stages of the disease when substantial retinal abnormalities are detected by retinal 
fundus imaging. Strategies to target early stages may be more efficacious, because 
they can prevent the onset of the severe and irreversible consequences. 
 
Diabetic retinopathy pathogenesis 
Despite DR being characterized clinically by vascular changes, many retinal cell 
types are affected before any detectable retinopathy is diagnosed. Neural cells, 
including photoreceptors, bipolar cells, and ganglion cells; vascular cells, including 
endothelial cells and pericytes; and glial cells, including macroglia (Müller cells and 
astrocytes) and microglia are all altered by diabetes (Figure 1). The causes of retinal 
cell dysfunction are interrelated, because each cell type has been demonstrated to 
produce both autocrine and paracrine factors that potentiate disease progression. 
Ultimately, retinal changes, including retinal neuron and pericyte death, glial and 
endothelial cell activation, and breakdown of endothelial cell junctions, are thought to 
increase in severity, eventually leading to overt signs of DR. 
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Figure 1. Retinal cells and their alterations in diabetic retinopathy. Adapted from Antonetti 
et al. (2012).31 This diagram depicts the laminar distribution of cells and relative localization in 
the retina. For orientation, vitreous is at the top of the image and sclera is at the bottom. In red 
on the right of the diagram, the alterations observed during diabetic retinopathy and discussed 
in the introduction are emphasized.  
 
Retinal neurons are among the most metabolically active cells in the body.32 
Thus, retinal neural cells are highly sensitive to diabetes-related retinal dyshomeostasis. 
Retinal neuronal death is an early component of diabetes, leading DR to be, at least in 
part, considered a neurodegenerative disease.33,34 Barber and colleagues observed 
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elevated neuronal cell death by TUNEL-positive staining in experimental diabetes 
models and patients with diabetes,35 validating earlier studies identifying neural cell 
death.36,37 These changes manifest clinically via multiple functional deficits. In patients 
with diabetes but without observable fundus changes, alterations were detected in 
diagnostic tests for retinal electrical activity (measured by electroretinograms (ERGs)), 
visual field, and contrast sensitivity – all are associated with neural dysfunction or cell 
death.38-46 
In response to diabetes, glial cells become reactive. There are two major subsets 
of glia in the retina, microglia and macroglia (astrocytes and Müller cells). While all glial 
cell types are responsive to diabetes, Müller glial cell reactivity is the focus of this 
dissertation and only their alterations are summarized. In experimental models of 
diabetes and in retinas from patients with DR, glial fibrillary activated protein (GFAP), a 
factor associated with glial activation, is elevated in Müller cells.47 Concomitant with 
increased GFAP levels, elevations in inflammatory factors are also observed.48 These 
inflammatory factors and their effects will be further discussed in the next section. Water 
handling by Müller cells is also changed by diabetes. Aquaporin (AQP) channels AQP1 
and AQP4 are predominantly found in macroglial cells in the retina. In models of DR, 
Müller cell AQP1 and AQP4 exhibit altered expression and localization, and these 
changes are thought to contribute to the increased liquid retention associated with 
diabetic macular edema.49,50 Müller cells are also the major handler of glutamate in the 
retina. Müller cells uptake extracellular glutamate that is used for neuronal transmission, 
thereby modulating the gain for synaptic signaling.51 In experimental models of DR, 
Müller cells have decreased glutamate uptake activity, suggesting that this dysfunction 
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may lead to glutamate cytotoxicity and neuronal cell death.51-53 Taken together, Müller 
cell changes are directly linked to various retinal functional deficits observed in DR, and 
thus limiting their activation may be an ideal target for treatment of early DR. 
 Diabetic retinopathy is clinically determined by alterations to the vasculature, and 
these changes are derived, in part, from endothelial cell dysfunction. Diabetes-induced 
vascular alterations include immune activation, loss of barrier function, and pericyte 
dropout; all of which can lead to vision-threatening pathology. The role of immune 
activation in diabetes-induced retinal pathology will be the focus of the next section. Yet, 
vascular inflammation, as well as hyperglycemia and elevated growth factors, 
contributes to blood-retina barrier (BRB) breakdown, and thus vascular permeability.54 
These diabetic stimuli are prominent in diabetes and interfere with endothelial tight 
junctions, leading to increased vascular permeability,55-59 a hallmark of DR. Vaso-
regression also contributes to loss of barrier function and is largely attributed to pericyte 
dropout. Pericytes are mural cells that associate closely with the endothelium, and 
pericyte-endothelial cell communication is necessary to maintain stable tight junctions.60 
For example, pericyte loss by genetic deletion of platelet-derived growth factor (PDGF) 
recapitulated vascular damage associated with STZ-induced DR.61 In retinal pericyte 
cell cultures, death can be initiated by both elevated glucose and fatty acids.62,63 
Additionally, pericyte death is observed in animal models of DR and retinas from 
diabetic patients.64,65 
Several animal models are used to recapitulate the disease outcomes for DR, 
and a summary of these models are listed in Table 1. The most commonly used and 
well-characterized model for DR is the streptozotocin- (STZ-) induced diabetes model, 
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which mimics complications associated with type 1 diabetes. In this model, the STZ 
alkylating agent is injected into rodents and taken up by GLUT2 receptors, which are 
highly expressed in the insulin-producing beta cells.66 This leads to DNA damage and 
consequent cell death specifically in pancreatic beta cells and thus the loss of insulin 
production. In this model, early events such as glial reactivity, vascular leakage, neural 
cell death, and inflammation occur around 8 weeks post-diabetes induction in mice.67-71 
Mouse models that mimic type 2 diabetes, such as the db/db (leptin-receptor deficient) 
or diet-induced obesity models, also develop retinal pathology similar to the STZ-treated 
animals,72-74 however, this pathology takes longer to develop due to the more gradual 
onset of insulin resistance and subsequent diabetes. 
 
Table 1. Summary of in vivo mouse DR models. 
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  To recapitulate specific steps observed in the chronic disease models, acute 
models are often used. One short-term model is the ischemia/reperfusion (IR) model, in 
which a temporary high intraocular pressure is exerted for about 120 minutes to create 
ischemia, followed by removal of the pressure source and reperfusion. This model 
recapitulates a variety of diabetes-relevant endpoints and allows for controlled dosing of 
therapeutic test agents. For instance, neuronal cell death, capillary dropout, vascular 
permeability, cell adhesion molecule expression, leukostasis, and cytokine up-regulation 
are all observed within 7 days from IR.75 Another way to model early disease 
pathogenesis is to inject either inflammatory cytokines, like TNFα, or growth factors, like 
VEGF, directly into the vitreous cavity. These factors rapidly induce a number of early-
stage disease processes, on the scale of hours, including leukostasis and vascular 
permeability.56,76,77 Chapter IV of this dissertation will describe experiments using 
intravitreal injection of TNFα as a means to develop proof of several concepts involving 
retinal inflammation. 
  Lastly, the oxygen-induced retinopathy (OIR) model is used to model PDR 
because no diabetic animal models have demonstrated retinal neovascularization similar 
to what is observed clinically in PDR. OIR animals do not have systemic diabetes and 
instead more accurately model retinopathy of prematurity (ROP), a disease that occurs 
in prematurely born infants. In the mouse OIR model developed by Lois Smith and 
colleagues,78 retinal vasculature develops in room air conditions (20.9% O2) for 7 days, 
followed by a hyperoxic exposure (75% O2) for 5 days, during which the central 
vasculature regresses. Animals are then returned to room air, and in the next 5-day 
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period pre-retinal pathologic neovascularization occurs in response to the central 
ischemic area in the retina, mimicking abnormal vascular growth observed in PDR.79 The 
vascular regression from hyperoxia more closely mimics ROP progression that was first 
observed in the 1950s and currently occurs in many developing countries.80 However, 
premature infants with very low birth weights (<2500g) have delayed vascular 
development as opposed to regressed vasculature, and this is more accurately modeled 
in the rat model of OIR developed by John Penn and colleagues.81,82 In this model, 
immediately upon birth when retinal vasculature has not yet developed, rats are exposed 
to a daily alternating oxygen concentration (50%/10% O2) for 14 days. At removal from 
alternating oxygen to room air, retinal vascular development has been delayed and a 
large avascular area is observed in the periphery, consistent with human ROP.83 The 
peripheral ischemic area drives hypoxia and up-regulates hypoxia-derived growth factors 
such as VEGF, which then promotes pathological neovascularization.84 Both models 
exhibit elevated inflammatory mediators as well as angiogenic factors that are observed 
in DR.79,85 While the mouse OIR model is used more frequently due to the advantage of 
genetic manipulation, the studies of angiogenesis in Chapter V of this dissertation will 
utilize the rat OIR model due to its greater physiologic relevance to human disease and 
our use of pharmacologic, rather than genetic, manipulations of the pertinent pathways. 
 
Inflammation in diabetic retinopathy 
 Inflammation is the body’s response to injury or pathogens and is critical for 
healing. This process is mediated by the interaction of leukocytes with endothelium 
upon activation by pro-inflammatory cytokines (e.g., TNFα or interleukins), chemokines, 
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or local chemo-attractants. These inflammatory factors are involved in drawing immune 
cells to injured or diseased tissues and activating endothelium to express cell adhesion 
molecules (e.g., VCAM-1, ICAM-1, selectins) that are involved in the rolling and 
tethering of leukocytes to the endothelial cell wall. When activated acutely, inflammation 
plays a beneficial role, such as in wound healing or infection resolution. However, when 
inflammation is chronically activated, such as in diabetes, rheumatoid arthritis, or 
atherosclerosis, tissue damage can occur. 
Retinal inflammation is a result of both circulating inflammatory factors and local 
inflammatory activation. In patients with DR, levels of inflammatory mediators in serum 
and vitreous are elevated. For example, Doganay and colleagues demonstrated a 
correlation of serum interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNFα) with the 
stage of DR. Patients with diabetes, but without DR, showed basal serum levels of IL-8 
and TNFα, while PDR patients had about double the serum levels of non-DR patients, 
and NPDR patients showed an intermediate amount of these inflammatory factors.86 
Furthermore, elevated cytokines (e.g., TNFα, IL-1β, IL-6, IL-8) are observed in the 
vitreous humor of patients with DR.22,87-91 These inflammatory factors have also been 
confirmed to be elevated in the retina of DR animal models.87,88,92 
 Several cell types, including retinal glia and endothelial cells, secrete soluble 
cytokines in response to diabetes-relevant culture conditions.93-95 Müller cells are 
particularly responsive to diabetic conditions. In both diabetic models and human DR 
retinal tissue, Müller cell GFAP is elevated, representing an activated state of this glial 
population.47,52,96 Activated Müller cells are known to elaborate several inflammatory 
and angiogenic mediators. For instance, in response to hypoxia, a stimulus that is 
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perhaps related to the late stages of DR, Müller cells were observed to be the major 
producers of VEGF compared to retinal astrocytes, microvascular endothelial cells, and 
retinal pigment epithelial cells.97 Furthermore, Müller-cell derived VEGF was found to be 
sufficient for induction of leukostasis and vascular permeability in the STZ-induced 
diabetes model and for pre-retinal neovascularization in an ischemia-induced 
retinopathy model.69,98 In Müller cells isolated from STZ-induced diabetic animals, 
several acute-phase inflammatory transcripts were significantly elevated, and this 
corresponded to elevated retinal IL-1β protein levels.48 There is precedence for IL-1β to 
amplify the inflammatory response by both paracrine and autocrine effects on the Müller 
cells.93,99,100 It is hypothesized that auto-amplification of these soluble cytokines may 
partially explain the delayed nature of DR pathology, because accumulation of 
inflammatory mediators may need to reach a threshold before retinal dysfunction is 
observed. This suggests that anti-inflammatory therapies administered early in the 
disease process would be highly efficacious because they would interrupt the cycle of 
chronic inflammatory cytokine elevation.101 While inflammatory mediator amplification 
can be assessed in vitro, culture conditions for inflammatory mediator induction have 
not been developed, and thus this is the goal of the studies reported in Chapter III of 
this dissertation. 
In response to the elevated inflammatory mediators, endothelial cells become 
activated, leading to the development of sight-threatening DR pathology as highlighted 
in Figure 2. The up-regulated inflammatory cytokines observed in DR patients (TNFα, 
IL-1β, IL-6, IL-8) are experimentally linked to leukostasis. In vascular cells, pro-
inflammatory cytokines induce expression of the adhesion proteins VCAM-1,102-104 
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ICAM-1102,104 and E-selectin,105,106 leading to leukocyte adhesion to the vessel wall.107-
109 The adhered leukocytes elaborate cytotoxic stimuli,110-112 which may promote 
pericyte and endothelial cell death.113,114 These events have been associated with 
retinal capillary occlusion and capillary dropout,115-117 leading to retinal ischemia and 
ultimately retinal hypoxia. In the later stages of disease progression, elevated retinal 
levels of hypoxia-inducible factors, such as VEGF, promote both hyperpermeability and 
neovascularization, the hallmark of PDR.  
 
 
Figure 2. The role of inflammation in diabetic retinopathy pathogenesis. Adapted from 
Zhang et al. 2011 (ref 88). This model demonstrates the close association of inflammation with 
the development of vision-threatening pathology in late stage DR. 
 
 Experiments in DR models have elucidated chronic retinal inflammation as a 
viable therapeutic target for early stage DR. For example, TNFα neutralization using the 
soluble TNFα receptor, Etanercept, reduced retinal inflammation and blood-retina-
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barrier (BRB) breakdown in a rat model of diabetes.118,119 Furthermore, blockade of 
ICAM-1 inhibited both VEGF- and diabetes-induced retinal inflammation and vascular 
leakage,117,120,121 thus suggesting a causative role of inflammation in vascular 
permeability. Pharmacologic anti-inflammatory strategies have also been studied for 
their potential efficacy in DR. COX-2 inhibition demonstrated efficacy in both rodent and 
dog models of diabetes by reducing leukostasis and vessel degeneration.118,122-124 
Conversely, in patients, aspirin has not exhibited substantial benefits in the 
clinic.101,125,126 Anti-inflammatory steroids, such as dexamethasone, have been shown to 
reduce ICAM-1, leukostasis, and vascular leakage, yielding positive outcomes for 
DR.101,127 However steroids carry the increased risk of glaucoma and cataract. Taken 
together, these findings suggest that inflammation is a viable therapeutic target, and 
there is a strong impetus to develop novel anti-inflammatory agents for treatment of DR. 
 
Epoxygenated fatty acids background 
Tissues metabolize fatty acids to biologically active lipid mediators through the 
cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 epoxygenase (CYP) 
pathways. There are 57 human genes that encode functional cytochrome P450 proteins 
and these enzymes are involved in metabolizing a wide variety of both endogenous and 
exogenous compounds.128 A subset of these enzymes has the ability to metabolize 
polyunsaturated fatty acids; enzymes of the CYP4 family possess hydroxylase activity 
and enzymes of the CYP2 family possess epoxygenase activity. CYP epoxygenase 
enzymes of the CYP2C and CYP2J families are the most highly characterized, however 
several CYPs in different families have been found to have epoxygenase activity.129 
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Epoxide products are derived from arachidonic acid (epoxyeicosatrienoic acid; EET), 
linoleic acid (epoxyoctadecaenoic acid; EpOME), eicosapentaenoic acid 
(epoxyeicosatetraenoic acid; EpETE), and docosahexaenoic acid 
(epoxydocosapentaenoic acid; EDP).130 This dissertation will focus on the enzymatic 
products of arachidonic acid (AA) and docosahexaenoic acid (DHA) because they have 
high relative mole percents compared to other polyunsaturated fatty acids in relevant 
retinal cells.131 CYP enzymatic activity yields four EET regioisomers from AA (5,6-EET, 
8,9-EET, 11,12-EET, and 14,15-EET) and five EDP regioisomers from DHA (7,8-EDP, 
10,11-EDP, 13,14-EDP, 16,17-EDP, and 19,20-EDP) via epoxide addition to any of the 
olefin bonds. These epoxides induce a variety of biological activities, including vaso-
dilatory, angiogenic, pro-survival, and anti-inflammatory actions.  
The tissue levels of these epoxides are primarily limited by the soluble epoxide 
hydrolase (sEH) enzyme, which hydrolyzes the epoxide group to yield diol products, the 
dihydoxyeicosatrienoic acids (DHETs) or dihydroxydocosapentaenoic acids (DHDPs). 
The diols are generally biologically inactive, and in some cases have opposing effects to 
their epoxide substrates.132,133 EETs and EDPs can also undergo chain elongation, β-
oxidation, or are incorporated into cell membranes, particularly when sEH is 
inhibited.134,135 The sEH enzyme is encoded by the EPHX2 gene, and functionally 
occurs as a homodimer of two 62-kDa monomers in the cytosol. The C-terminal domain 
of the enzyme possesses epoxide hydrolysis activity while the N-terminal domain has 
phosphatase activity; the functional relevance of this phosphatase activity in mammals 
remains unclear.136 sEH metabolizes epoxide regioisomers at different rates, based on 
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the proximity of the epoxide group to the carboxylic acid.137 Notably, DHA-derived 
epoxides are better substrates for sEH, with the exception of 19,20-EDP.138  
 
Figure 3. Structures of CYP substrates (AA and DHA), CYP products (EET and EDP), and 
sEH products (DHET and DHDP). 
 
Activities of epoxygenated fatty acids 
While no specific EET or EDP receptor has been identified, epoxides have been 
shown to exert their activities through a number of signaling pathways (Figure 4). EET 
signaling has been studied more than EDP, and thus most of what is known about 
epoxide signaling is from EET studies. Evidence suggests that EETs may activate 
intracellular signaling cascades through the activation of GPCRs. Treatment of cells 
with exogenous EETs increases adenosine 3’5’-cyclic monophosphate (cAMP) and 
protein kinase A (PKA), and this may be mediated through Gαs.135,139,140 Generation of 
cAMP may be, in part, attributable to EET activation of prostaglandin receptors.141 More 
recently, EET has been shown to exert its mitogenic effects through the lipid-binding 
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GPCR, GPR40.142 Peroxisome proliferator-activated receptors (PPARs), a family of 
transcription factors that bind a variety of ligands to exert functions predominantly 
related to lipid metabolism and cell differentiation, have also been shown to mediate 
EET biological activities.143-145 Additional intracellular signaling cascades are activated 
in response to EET stimulation, including MAPK and PI3K/Akt as well as inhibition of 
IKK.146-149 Due to the wide range of cellular influences, EETs may serve as ligands to a 
variety of receptors, and not necessarily a single, unidentified EET-specific receptor. 
 
Figure 4. Signaling pathways and activities regulated by EET. EDP-induced behaviors were 
not included because they have not been thoroughly studied. Figure adapted from Spector & 
Norris 2007 (ref 135). 
 
The effects of EETs have been most thoroughly studied in regards to endothelial 
cell behaviors. Interest in AA-derived epoxides stemmed from their identification as 
endothelial-derived hyperpolarizing factors (EDHFs) due to their NO- and PGI2-
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independent vaso-relaxation via KCa activation in bovine coronary arteries.150,151 EDPs 
also demonstrated similar vaso-activity, and in certain vascular beds they were more 
potent vaso-dilatory agents.152,153 Several studies verified the effects of EETs and EDPs 
on vaso-relaxation, making it the most studied behavior induced by CYP-derived 
epoxides. Due to potent vaso-dilatory effects of the epoxides, sEH inhibition was 
assessed in clinical trials for treatment of moderate hypertension (NCT00847899). 
Though the inhibitor AR9281, developed by Arete Therapeutics, did not result in any 
adverse events, sEH inhibition was not efficacious for hypertension in phase II clinical 
trials.137,154 
EETs also possess potent pro-angiogenic activities, and these activities have 
been most widely studied in the field of cancer.155 CYP-derived EET production has 
been shown to play a significant role in promoting endothelial cell proliferation and 
mitogenesis.156,157 Particularly relevant to retinal vaso-proliferative disease, some CYPs 
are regulated by hypoxia. Although CYP2J2 was down-regulated in hypoxia, CYP2C8/9 
enzymes were hypoxia-inducible in human umbilical vein endothelial cells (HUVEC) and 
bovine retinal microvascular endothelial cells (BRMEC).158,159 The hypoxia-induced EET 
products are downstream signaling intermediates in the VEGF signaling pathway;149,160 
accordingly, CYP inhibitors reduced EC proliferation and overexpression of CYP2C8 
promoted EC proliferation in vitro.161 A number of in vivo studies also support a role for 
EETs in angiogenesis. For example, administration of exogenous EETs induced 
vascularization in the Matrigel plug assay, and overexpression of rat CYP2C11 
increased muscle capillary density in an ischemic rat hind limb model.148,162 
Furthermore, increased EET production promoted tumor growth and metastases in a 
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number of in vivo cancer models.153,155,163 Conversely, EDPs appear to be anti-
angiogenic. In matrigel plug and tube formation assays, 19,20-EDP dose-dependently 
inhibited VEGF-induced angiogenesis.164 Additionally, Kip Connor’s group observed a 
significant reduction of choroidal angiogenesis with systemic 19,20-EDP administration 
in the laser-induced choroidal neovascularization model.165 Contrary evidence has been 
suggested by Lois Smith’s group, in which they postulate that endothelial cell-specific 
CYP overexpression promotes retinal neovascularization in the OIR mouse model when 
mice were fed an ω-3 rich diet.166 However, Hu et al. showed that physiologic 
angiogenesis was driven by the diol product of 19,20-EDP, 19,20-DHDP,132 suggesting 
that the elevated angiogenesis observed with CYP overexpression may be attributed to 
sEH products. Further work is necessary to understand the role of DHA-derived 
epoxides in pathological retinal angiogenesis. 
In 1999, Node and colleagues first demonstrated the anti-inflammatory effects of 
EETs. In bovine aortic endothelial cells, TNFα induced the translocation of a pro-
inflammatory transcription factor, NFκB; 11,12-EET inhibited TNFα-induced NFκB 
translocation via inhibition of IκBα degradation, thus reducing the transcription of VCAM-
1, a well-characterized NFκB target gene.146 Subsequent studies have validated this 
response in a variety of contexts, and these studies will be elaborated in the next 
section.  
A limited amount of information is known regarding EETs and EDPs in retinal 
tissue. CYP2C8 exhibited the highest expression among the CYP epoxygenases 
examined in post-mortem human retinal tissue with no ocular disease.167 Its murine 
functional homolog, Cyp2c44, was also shown to be highly expressed in the retina, 
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localizing primarily to capillary pericytes and glia.168 In the developing mouse retina 
19,20-DHDP mediated developmental angiogenesis; thus, sEH deletion slowed the 
developing vascular network.132 Interestingly, deletion of Müller cell-specific Ephx2 (the 
gene coding sEH) recapitulated the vascular development phenotype of the whole body 
Ephx2 KO,169 suggesting that Müller cells may be the primary source of epoxide 
hydrolysis in the retina. The 11,12-EET regioisomer and the 19,20-EDP regioisomer 
were found to be the most abundant in the retina,151,169 and thus are the primary EET 
and EDP regioisomers used in the experimental work of this dissertation. 
 
Epoxygenated fatty acids in inflammation 
Several in vitro studies using various inflammatory stimuli have identified an anti-
inflammatory role for EETs. Limited mechanistic studies have been performed using 
EDPs, however overexpression of CYPs or genetic/pharmacologic reduction of sEH 
activity likely elevates EETs and EDPs similarly. As described above, the anti-
inflammatory capacity of EETs was first identified in bovine aortic endothelial cells; 
CYP2J2 overexpression and 11,12-EET treatment inhibited TNFα-, IL-1β-, and LPS-
induced VCAM-1 expression by preventing activation of NFκB.146 EET anti-inflammatory 
activity via NFκB inhibition has been validated in other macrovascular endothelial cells 
and monocytes.103,170-174 Anti-inflammatory activities have also been attributed to EET 
activation of PPARα and PPARγ.143-145,175 The gene targets of these signaling pathways 
include cell adhesion molecules and chemokines. Thus, pulmonary EC derived from 
mice overexpressing human CYP2J2 or -2C8 exhibited reduced levels of LPS-induced 
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adhesion molecule and chemokine expression, and the CYP inhibitor MS-PPOH and a 
putative EET antagonist 14,15-EEZE nullified these anti-inflammatory effects.176 
Evidence from in vivo studies also supports the anti-inflammatory effects of EET 
and EDP. Rats injected with TNFα showed elevated plasma levels of cytokines and 
soluble forms of adhesion molecules, and decreased levels of the anti-inflammatory 
cytokine IL-10; normal levels were recovered by systemic overexpression of human 
CYP2J2.177 In a model of cerebral ischemia, EC-specific human CYP2J2 or -2C8 
reduced infarct size while also reducing levels of TNFα and IL-1β transcripts.178 
Similarly, Ephx2-/- mice and mice overexpressing EC-specific human CYP2J2 or -2C8 
all showed reduced levels of inflammatory gene expression and neutrophil recruitment 
in the lung following LPS injection.176 These effects might also be mediated by 
alterations in monocyte behavior. In a model of sterile resolving peritonitis, EETs were 
involved in resolution of inflammation by clearance of pro-inflammatory monocytes; pro-
inflammatory monocyte accumulation was increased by CYP inhibition using SKF-525A 
and was reduced by sEH deletion.179 Pharmacologic manipulation of sEH produces 
similar anti-inflammatory responses. For example, in a mouse model of acute 
inflammation induced by systemic LPS, pharmacologic inhibition of sEH reduced 
plasma TNFα and IL-6 levels compared to vehicle treatment.180 Likewise, sEH inhibition 
mitigated high fat diet-induced hepatic IL-1β up-regulation, and increased IL-10 in DHA-
enriched fat-1 animals, suggesting an influence by EDP.181 Together, these data 
confirm a role for EET/EDP in inhibition of vascular cytokine production and leukostasis. 
Furthermore, the inflammatory mediators that are the focus of this dissertation, TNFα, 
IL-1β, IL-6, and IL-8, all have proven to be regulated by CYP-derived epoxides.181-185 
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Though epoxides demonstrate potent anti-inflammatory activities, in inflamed 
tissues their beneficial effects are limited by alterations in the normal balance of 
CYP/sEH enzyme levels. For example, in mice receiving intraperitoneal LPS injections 
CYP epoxygenase expression and EET product formation were reduced in the liver, 
kidney, and lungs.186 Furthermore, distinct cytokines have differential effects on hepatic 
CYP expression.187 Conversely, sEH expression is elevated in various models of 
inflammation. For example, in macrophages from diabetic animals, LPS stimulation 
increased sEH expression, and this induction was even greater than in macrophages 
from control mice.188 Additionally, sEH levels were elevated at the graft-vein junction in 
a porcine model of arteriovenous grafts, and this elevation was confirmed in cultured 
monocytes.189 Taken together, these data suggest that CYP and sEH dysregulation 
contributes to a cycle of chronic inflammation initiated by cytokine elevation; cytokines 
attenuate CYP levels and elevate sEH levels, thereby decreasing anti-inflammatory 
epoxides. The decreased epoxide levels consequently create a permissive environment 
for persistent inflammation. 
 
Epoxygenated fatty acids in diabetes and obesity 
In a wide range of diabetes-relevant culture conditions, CYP-derived epoxides 
exert anti-iflammatory effects. For example, homocysteine, which is elevated in diabetic 
retinopathy and associated with atherosclerosis,190,191 induces NFκB activity in mouse 
aortic endothelial cells and CYP2J2 overexpression reduced this activation.173 Palmitic 
acid, which is elevated in the serum and tissues of diabetic patients and animal 
models,192-194 induced TNFα, IL-1β and IL-6 up-regulation in HepG2 cells, while CYP2J2 
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overexpression and 14,15-EET inhibited this induction.195,196 EETs are also able to 
modulate the activity of immune cells and macrophages in culture. For example, 
peripheral blood mononuclear cells (PBMC) isolated from Ldlr-/- mice, which have 
elevated serum cholesterol, show increased adherence when rolled over P-selectin-
coated plates or TNFα-treated endothelial cell monolayers; treatment with soluble 
epoxide hydrolase inhibitors plus 14,15-EET or co-deletion of sEH decreased PBMC 
adhesion.197 Thus, epoxide anti-inflammatory activities have been observed in several 
diabetes-relevant culture conditions using cells derived from a variety of tissue beds. 
CYP and sEH enzymes have been investigated in diabetic animals and patients, 
and in the related contexts of hypertension and metabolic syndrome. The overwhelming 
majority of evidence supports a protective role of EET and EDP, and points to altered 
CYP and sEH levels and compromised EET/EDP production under diabetic conditions. 
STZ-treated diabetic mice that underwent experimental occlusion of the middle cerebral 
artery exhibited increased sEH in cerebral vessels and decreased EET levels in brain, 
relative to non-diabetics.198 The diabetic mice sustained larger brain infarct than 
controls, and pretreatment with an sEH inhibitor eliminated this difference and 
normalized EET concentrations, without altering glycemia.198 In the db/db mouse model 
of diabetes, systemic CYP2J2 overexpression reduced activation of the NFκB signaling 
pathway in liver, leading to decreased production of TNFα, IL-1β and IL-6.196 sEH 
inhibition also decreased ICAM-1, VCAM-1 and IL-6 expression and macrophage 
infiltration in aortic vessels of ApoE-/- mice treated with angiotensin II.199 Furthermore, 
sEH deletion or inhibition attenuated STZ-induced diabetic nephropathy and reduced 
renal phospho-IKK to total IKK ratios, indicating less activation of NFκB.200 
	 25 
together, these data provide the basis for epoxide therapies as a potential anti-
inflammatory therapy for early DR. 
In a variety of in vitro and in vivo experimental settings, diabetes-relevant 
conditions consistently perturb CYP and sEH expression, reducing EET/EDP levels.201-
206 The results of these studies are summarized in Table 2. In porcine aortic endothelial 
cells (EC) treated with high glucose, CYP expression and activity were significantly 
decreased within 24 hours, resulting in reduced EET production.204 Homocysteine 
induced sEH expression in endothelial cells, and consequently sEH inhibition mitigated 
homocysteine-induced VCAM-1 expression.207 Additionally, sEH was up-regulated in 
HepG2 cells treated with PA, leading to increased endoplasmic reticulum (ER) stress.206 
In the Zucker obese rat model, expression of the rat homologs of human CYP2C 
enzymes, CYP2C11 and CYP2C23, were decreased in renal and mesenteric arteries, 
while sEH expression was increased.201,205 Studies in diet-induced hypertensive or 
obese Zucker rats, models of type 2-related pre-diabetes, demonstrated that protein 
levels of CYP2C11 and -2C23 were significantly decreased in kidney vasculature, 
correlating with endothelial dysfunction, microalbuminuria and hypertension.208-211 
Additionally, in the rat STZ diabetes model, hepatic CYP2C11 was almost completely 
absent by 4 weeks post-diabetes induction.212 Lastly, and of particular relevance to the 
hypothesis of my project, 11,12-EET and 14,15-EET are significantly reduced in the 
vitreous of patients with DR compared to non-diabetic controls.89 Taken together, these 
findings suggest that during diabetes CYP and sEH expression are altered in a way that 
reduces EETs and EDPs, causing a permissive environment for inflammation in diabetic 
retinopathy. 
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Table 2. Summary of studies observing alterations to enzyme and/or epoxide levels. 
 
Apart from their expected effects on inflammation, EET/EDP-elevating strategies 
have other beneficial features. For example, STZ-treated Ephx2-/- mice or WT mice 
treated with sEH inhibitors exhibited increased glucose tolerance, and Ephx2-/- mice 
maintained on high fat diets showed decreased insulin resistance.213,214 Similarly, 
CYP2J3 overexpression in db/db mice and fructose-fed rats resulted in decreased 
peripheral insulin resistance.215 Also, obese Ephx2-/- mice exhibited elevated kidney 
EET levels, accompanied by improved vascular function in the kidney compared to 
obese control mice.216 In activity-restricted primates, decreased capillary blood volume 
is associated with an increased ratio of vaso-constrictor HETEs to vaso-dilatory EETs, 
and this correlated with insulin resistance.217 A recent study further suggests that EETs 
have a direct role in hepatic insulin sensitivity because EET treatment increased Akt 
activity without affecting insulin receptor or insulin receptor substrate-1 levels.218 These 
outcomes suggest added benefits of therapeutic epoxide manipulation in diabetes and 
	 27 
its complications.  
Several clinical studies have verified the results of these in vitro and in vivo 
studies. For instance, plasma EET levels are decreased in patients with metabolic 
syndrome.219 Furthermore, a G50T polymorphism in CYP2J2, resulting in decreased 
expression and activity, was significantly associated with early type 2 diabetes onset.220 
A close association has also been identified between a G860A polymorphism in the 
EPHX2 gene and elevated insulin resistance in type 2 diabetics.221 These findings point 
to an important role for sEH regulation of epoxide levels in diabetes and demonstrate 
the safety of therapeutic sEH inhibition. Further supporting this concept, sEH inhibitors 
have been used clinically for impaired glucose tolerance and hypertension.222-226 
Based on the role of EETs and EDPs in inflammation, and their decreased levels 
in various tissue beds affected by diabetes, I hypothesized that endogenous EET/EDP 
levels would be decreased in response to diabetes-relevant conditions, and thus their 
experimental elevation would be efficacious in treating early stages of DR. In order to 
test this hypothesis, I have employed several pharmacologic manipulations to alter the 
enzyme activities and/or epoxide levels involved in the pathway. The relevant metabolic 
pathways, as well as these experimental manipulations, are outlined in Figure 5.  
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Figure 5. Overview of the CYP/sEH pathway and experimental manipulations used in this 
dissertation. Tools used to limit EET/EDP production are shown in red (SKF-525A) and tools 
used to increase EET/EDP levels are shown in green (11,12-EET, 19,20-EDP, AUDA, and 
GSK2256294). 
 
In the following chapters, I sought to address this hypothesis by analyzing the 
effect of epoxides in disease-relevant in vitro and in vivo models of retinal inflammation 
and angiogenesis. In Chapter III, I established diabetes-relevant in vitro models for 
Müller cells that can be used to determine the effect of EETs and EDPs on initiation and 
amplification of inflammatory factors. Next, in Chapter IV, I examined the paracrine 
effects of inflammatory mediators on endothelial cells and determined the role of EET 
and EDP manipulation on retinal vascular inflammation. A visual model demonstrating 
my hypothesis regarding EET/EDP in retinal inflammation during DR is shown in Figure 
6. Lastly, I demonstrated in Chapter V that retinal angiogenesis is promoted by EETs, 
suggesting that pharmacologic strategies developed to elevate their levels may be 
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contraindicated for late-stage diabetic retinopathy. The results of these studies provide 
a basis for understanding and further exploring the role of epoxides in the pathogenesis 
of DR. 
 
Figure 6. Hypothetical model of the role of epoxides in early diabetic retinopathy.   
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CHAPTER II 
 
METHODS 
Human Retinal Cell Culture 
Human Müller cell isolation, culture and treatment 
Primary human retinal Müller Cells were isolated from human donor tissue 
(NDRI) within 24hrs post-mortem, using a modified protocol developed by Hicks and 
Courtois.227 The retina was dissected from the eye cup and dissociated in Dulbecco’s 
Modified Eagle Medium (DMEM; Life Technologies) containing trypsin and collagenase. 
Following incubation in dissociation medium, cells were cultured in DMEM containing 
10% fetal bovine serum (FBS) and 1x antibiotic/antimycotic solution. Passages 4 
through 6 were used for all experiments. 
In Chapter III, Müller cells were cultured in 6-well dishes and at 70% confluence, 
Müller cells were cultured in serum-reduced conditions (2% FBS) for 12 hours before 
treatment. Cells were then treated in serum-reduced medium containing either elevated 
D-glucose (30.5mM) or L-glucose (osmotic control; 5.5mM D-glucose plus 25mM L-
glucose) for 24 hours. Next, medium was removed and replaced with the same D-
glucose or L-glucose treatment in the presence of either BSA-bound palmitic acid (PA; 
250µM) or fatty acid-free BSA control (100mg/ml in PBS). PA was prepared at 200mM 
in EtOH. Once dissolved, PA in EtOH was incubated with 100mg/ml BSA in PBS at 
5mM for 90 minutes at 37°C before added to media. The treatment groups in Chapter 
III are therefore referred to as the following: LG/BSA (L-glucose 24 hours, L-glucose + 
BSA 24 hours), LG/PA (L-glucose 24 hours, L-glucose + PA 24 hours), DG/BSA (D-
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glucose 24 hours, D-glucose + BSA 24 hours), or DG/PA (D-glucose, D-glucose + PA 
24 hours). 
For cytokine stimulation of Müller cells, cells were cultured in 6-well plates, and at 
80% confluence, cells were placed in serum-reduced conditions for 12 hours. Cells 
were then treated for either 2, 4, 8, 12, or 24 hours with 1ng/ml of the following human 
recombinant proteins: TNFα (Millipore), IL-1β (R&D Systems), IL-6 (R&D Systems), or 
IL-8 (R&D Systems).  
In Chapter V, Müller cells were seeded in 6-well plates at 2x105 cells/well and 
maintained under standard culture conditions, as described above. At 90% confluency, 
cells were exposed to either normoxia (20.9% O2) or hypoxia (0.1% O2) for 24 hours. 
Oxygen levels were maintained at 0.1% using the ProOx 110 (BioSpherix). 
 
Human retinal microvascular endothelial cell culture and treatment 
Primary human retinal microvascular endothelial cells (HRMEC; Cell Systems) 
were validated by assessing cytoplasmic VWF and uptake of Di-I-Ac-LDL. Cells were 
cultured in phenol red-free endothelial basal medium (EBM; Lonza) containing 10% 
FBS with SingleQuots (Lonza) and grown on attachment factor- (Cell Signaling) coated 
culture dishes. Cultures were incubated at 37°C, 5% CO2, and 20.9% O2 and 95% 
relative humidity. Passages 6 to 10 were used for all experiments. 
In Chapter IV, endothelial cells were treated in 100cm2 plates (for epoxide 
quantification), 6-well plates (for qRT-PCR), 10cm2 dishes (for immunoblots), glass 
microscope slides (for PPFC), or 96-well plates (for NFκB activity assay). Unless 
otherwise specified, cells were placed in serum-reduced media (2% FBS), which 
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contained 1x antibiotic/antimotic instead of Singlequots, for 12 hours. Cells were then 
treated with vehicle (0.3% EtOH and 0.1% DMSO), TNFα (1ng/ml) plus vehicle, or 
TNFα plus 11,12-EET (0.5µM), 19,20-EDP, 12-(3-adamantane-1-yl-ureido)-dodecanoic 
acid (AUDA; 10µM), 11,12-DHET (0.5µM), 19,20-DHDP (0.5µM), or combinations of 
11,12-EET or 19,20-EDP and AUDA. 
In Chapter V, human retinal microvascular endothelial cells were seeded in 6-
well plates at 2x105 cells/well and maintained under standard culture conditions, as 
described above. For hypoxia experiments, at 90% confluency, cells were exposed to 
either normoxia (20.9% O2) or hypoxia (0.1% O2) for 24 hours. Oxygen levels were 
maintained at 0.1% using the ProOx 110 (BioSpherix). 
 
Human retinal astrocyte cell culture and treatment 
Primary cultures of human retinal astrocytes (Sciencell) were plated in tissue 
culture flasks coated with poly-L-lysine (Sciencell). Astrocytes were cultured in 
Astrocyte Growth Medium (Sciencell), containing 2% fetal bovine serum (FBS), 
astrocyte growth supplement, and a penicillin/streptomycin solution. Cultures were 
incubated at 37°C, 5% CO2, 20.9% O2, and 95% relative humidity. Passages 4 to 6 
were used. In Chapter V, human retinal astrocytes were seeded in 6-well plates at 
2x105 cells/well and maintained under standard culture conditions, as described above. 
At 90% confluency, cells were exposed to either normoxia (20.9% O2) or hypoxia (0.1% 
O2) for 24 hours. Oxygen levels were maintained at 0.1% using the ProOx 110 
(BioSpherix). 
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RNA isolation, RNAseq, and analysis 
 Treated cells were lysed and RNA purified using the RNeasy mini kit (Qiagen) 
according to the manufacturer’s protocol. Total RNA was isolated and submitted to the 
Vanderbilt Technologies for Advanced Genomics (VANTAGE) core for RNAseq 
analysis. RNA sample quality was confirmed using the 2100 Bioanalyzer (Agilent 
Technologies; Santa Clara, CA). All RNA samples had an RNA integrity number > 8.0. 
Samples were prepared for sequencing using the TruSeq RNA Sample Prep Kit 
(Illumina; San Diego, CA) to enrich for mRNA and prepare cDNA libraries. Library 
quality was assessed using the 2100 Bioanalyzer. Sequencing was performed using a 
single read, 75 bp protocol on the Illumina HiSeq 3000 (Illumina). This method was 
used in Chapter III. 
 
Alignment and differential expression 
 The Vanderbilt Technologies for Advanced Genomic Analysis and Research 
Design (VANGARD) core performed sequence alignment and differential expression 
analyses. Alignment and gene mapping was performed using QC3.228 Differential 
expression was assessed using MultiRankSeq, which uses the results of three 
statistical algorithms (DESeq, edgeR, and baySeq) to more rigorously determine 
significantly altered gene transcripts.229 Briefly, each algorithm generates a rank of 
differentially expressed genes based on statistical significance of differential read 
counts. These ranks are summed, generating a list of transcripts with the greatest 
differential expression by all three algorithms. For analysis, only transcripts with an 
adjusted p-value <0.05 determined by any two (L-glucose vs. D-glucose and L-
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glucose/PA vs. D-Glucose/PA) or all three (BSA vs. PA and vehicle vs. cytokines) 
algorithms were used for analysis. This method was used in Chapter III. 
 
Pathway analysis 
 Pathway enrichment analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID; v6.7). Lists of significantly up-regulated 
genes were submitted to the DAVID website and compared to a human reference gene 
background. The Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway 
annotation and Biocarta annotation (only PA-treated Müller cells) was used for pathway 
enrichment analysis. Pathways were considered significantly enriched with p<0.05.  
This method was used in Chapter III. 
 
Quantitative real time RT-PCR 
After treatment, cells were washed twice with cold PBS and total RNA was 
collected using the RNeasy Mini kit (Qiagen). Total RNA isolated from the culture wells 
was reverse transcribed using the High-Capacity cDNA Archive Kit (Applied 
Biosystems). Quantitative RT-PCR was performed in duplicate by co-amplification of 
cDNA vs. a normalization control (either 18S or ACTB), using gene-specific TaqMan 
Gene Expression Assays (Table 3; Applied Biosystems). The delta Ct method was used 
to determine relative expression of the targeted mRNA normalized to the selected 
normalization control. All commercial assays were performed according to the 
manufacturer’s protocol. This method was used in Chapters III-V. 
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Table 3. Gene expression assays used in studies. 
 
Immunocytochemical analysis 
After treatment, cells were fixed with 4% paraformaldehyde in PBS for 30 
minutes. Cells were then washed three times in PBS containing 0.1% Triton-X 100 in 
PBS (PBST) for 15 minutes each, followed by blocking in 4% BSA in 0.3% PBST for 1 
hour at room temperature. Cells were then incubated in primary antibodies for glial 
fibrillary acidic protein (GFAP; 1:2000; Agilent Technologies) or glutamine synthase 
(GS; 1:250; Millipore) in blocking buffer overnight at 4¹C. Cells that were incubated 
without primary served as a negative control. After incubation in primary, cells were 
washed and then were incubated with secondary antibody (1:1000; Thermo Fisher 
Target Primer Species Chapter 
IL8 Hs00174103_m1 Human 3 
MMP1 Hs00899658_m1 Human 3 
PTGS2 Hs00153133_m1 Human 3 
PTGIS Hs00919949_m1 Human 3 
18S Hs99999901_s1 Human 3,4 
TNFA Hs01113624_g1 Human 3 
IL1B Hs01555410_m1 Human 3 
IL6 Hs00985639_m1 Human 3 
VCAM1 Hs01003372_m1 Human 4 
ICAM1 Hs00164932_m1 Human 4 
CYP2C8 Hs02383390_s1 Human 5 
CYP2C9 Hs02383631_s1 Human 5 
CYP2C11 Rn01502203_m1  Rat 5 
CYP2C23 Rn00582954_m1 Rat 5 
ACTB Rn00667869_m1 Rat 5 
ACTB Hs01060665_g1  Human 5 
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Scientific) for 1 hour at room temperature. After washing in PBST, cells were mounted 
in Vectashield Hardset with DAPI mounting media (Vector Laboratories) and images 
were captured with an AX70 upright microscope (Olympus) and DP71 digital camera 
(Olympus) at 20x magnification. This method was used in Chapter III. 
 
Epoxygenated fatty acid quantification 
Human Müller cells (Appendix C) or HRMEC (Chapter IV) were treated for 21 
hours or 9 hours, respectively, followed by treatment with EET and EDP substrate 
(10µM AA and 10µM DHA; Sigma-Aldrich) for 3 hours. Media was collected, 
triphenylphosphine (TPP; Sigma-Aldrich) was added, and samples were evacuated with 
argon. After adding synthetic [2H11]-labeled 8,9-DHET, 11,12-DHET, 14,15-DHET, 
16,17-DHDP, and 19,20-DHDP (5ng each) as internal standards, the EET/EDPs and 
DHET/DHDPs were extracted with acidified CHCl3/CH3OH (2:1) and purified by silica 
solid phase extraction, separating EET/EDPs and DHET/DHDPs. The EET/EDPs were 
converted to the corresponding DHET/DHDPs by treatment with acetic acid overnight. 
The samples were quantified by LC/MS/MS using an Acquity BEH C18 columns (1.0 × 
100mm; 1.7µm) connected to a TSQ-Quantum Vantage triple quadrupole spectrometer 
(Thermo Fisher Scientific). DHET/DHDP positional isomers were resolved using a linear 
solvent gradient that went from 70% 15mM aqueous ammonium acetate (pH 8.5), 30% 
acetonitrile to 40% 15mM aqueous ammonium acetate (pH 8.5), 60% acetonitrile in 6 
minutes and at a flow of 0.18ml/min. For analysis, we utilized collision-induced 
fragmentation of the DHET/DHDPs at m/z 337 and the [2H11]-DHET/DHDP internal 
standards at m/z 448. These same product ions were also used for the deuterated 
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internal standards. Quantifications were done using the ratio of the area of the 
DHET/DHDP peaks compared to the area of the corresponding deuterated 
DHET/DHDP peaks. Cell lysates were collected, total protein was measured using a 
Pierce bicinchoninic acid assay (BCA; Thermo Fisher Scientific), and EET and EDP 
levels were normalized to the total protein. This method was used in Chapter IV. 
 
Immunoblot analysis 
After treatment, cells were washed twice in cold PBS and lysed using radio-
immunoprecipitation assay (RIPA) buffer (Qiagen) with protease inhibitors (Roche). 
Samples were equilibrated for total protein concentration using a BCA assay (Pierce), 
and prepared in 4x Laemmli Buffer (Bio-Rad) containing 355mM β-mercaptoethanol 
(Bio-Rad) and then heated for 10min at 96°C. Fifteen µg of protein were loaded onto a 
10% SDS gel (Bio-Rad) and the gels were run for 1 hour and 45 minutes. Samples were 
then transferred to nitrocellulose membranes using the iBlot system (Thermo Fisher 
Scientific). Membranes were blocked and probed in 5% BSA for CD54/ICAM-1 (1:1000; 
Cell Signaling) and β-Actin (1:4000; Thermo Fisher Scientific) or 5% milk for VCAM-1 
(1:1000; Abcam) Blots were then labeled with horseradish peroxidase-conjugated 
secondary antibodies (1:2000). β-Actin was used as a loading control. Membranes were 
incubated in Pierce ECL Western blotting substrate and developed with a ChemiDoc 
MP (Bio-Rad). Blots were then quantified using ImageJ software. This method was used 
in Chapter IV. 
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Parallel plate flow chamber 
HRMEC were plated on glass slides coated with attachment factor. Once 
confluent monolayers formed, cells were placed in serum-reduced culture medium for 
12 hours and then treated as stated for 4 hours. After treatment, slides were placed in a 
parallel plate flow chamber (GlycoTech), as described previously.76 PBMC (Sanguine 
Biosciences) were resuspended in Hank’s Buffered Salt Solution (HBSS) at a 
concentration of 5 x 105 cells/ml. Cells were then flowed over treated monolayers at a 
shear stress of 1dyn/cm2 for 7 minutes, and non-adherent cells were then removed with 
HBSS at 2dyn/cm2 for 2 minutes. Eight fields were randomly captured and adhered 
leukocytes were counted by a masked observer. Data are shown as the average of the 
eight captured fields for one slide and reported as adherent cells per mm2. This method 
was used in Chapter IV. 
 
NFkB activity assay 
HRMEC were seeded on 96-well black-walled, clear bottom plates. Each well 
was transfected with NFkB-responsive luciferase constructs, negative control 
constructs, or positive control constructs from the Cignal NFkB Reporter Assay 
(Qiagen). For transfection, 75µL of fresh 10% media was added to each well 30 minutes 
prior to treatment. Each well was then transfected with 200ng of each construct, 1.8µL 
of Targafect solution A (Targetingsystems), and 3.6µL Virofect (Targetingsystems) in 
50µL of Optimem (Life Technologies). The transfection mix was prepared in a separate 
tube, and 15 inversions were performed between the additions of each reagent. After 
preparation, the transfection mix was incubated at 37°C for 25 minutes. Twelve hours 
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after initiation of transfection, cells were washed and treated with fresh 10% medium for 
12 hours. Twenty-four hours post-transfection, cells were treated with vehicle or TNFα 
(1ng/ml) in the presence or absence of 11,12-EET (0.5µM) or 19,20-EDP (0.5µM) with 
AUDA (10µM) for 24hrs after initiating transfection. Luciferase was quantified using the 
Dual-Glo Luciferase Assay System (Promega), according to the manufacturer’s 
protocol. Data are reported as the relative ratio of firefly-to-Renilla luciferase. This 
method was used in Chapter IV. 
 
Intravitreal injection 
All experiments were approved by the Vanderbilt University Institutional Animal 
Care and Use Committee and were performed in accordance with the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research. Rodents were anesthetized 
by isoflurane (Butler Animal Health Supply) inhalation. Before intravitreal injection, 0.5% 
proparacaine (Allergan) was topically applied to the cornea. The globe was penetrated 
approximately 0.5mm posterior to the ora serrata, using a 30-gauge needle with a 19° 
bevel and a 10µL syringe (Hamilton Co.). The needle was advanced to the posterior 
vitreous at a steep angle to avoid contact with the lens. The injection bolus was 
delivered near the trunk of the hyaloid artery proximal to the posterior pole of the retina. 
After injection, a topical antibiotic suspension (Vigamox; Alcon) was applied. In Chapter 
IV, 6 week-old C57BL/6J mice (Charles Rivers) were injected intravitreally with 2µl of 
vehicle (0.1% DMSO and 0.3% EtOH), TNFα (50ng/ml), TNFα with 11,12-EET (0.5 µM) 
plus AUDA (10µM), or TNFα with 19,20-EDP (0.5µM) plus AUDA (10µM). In Chapter V, 
at 14(0) and 14(3) Sprague-Dawley rat pups received intravitreal injections (5µL) of 
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vehicle (0.1% ethanol in PBS) or increasing concentrations of SKF-525A (0.5µM – 
5.0µM). This method was used in Chapter IV and V. 
 
Retinal leukostasis 
Six hours after treatment, mice were anesthetized with ketamine (100mg/kg) and 
xylazine (10mg/kg) and perfused with 0.9% saline for 1min, followed by FITC-
conjugated concanavalin-A (40µg/ml in 2.5ml PBS; Vector Laboratories) at a rate of 
6.5ml/min. Mice were then perfused with saline for 5mins to remove any non-adherent 
leukocytes. Retinas were immediately dissected into 4% paraformaldehyde, flat-
mounted, and images were captured with an AX70 upright microscope (Olympus) and 
DP71 digital camera (Olympus) at 4x magnification. Adherent leukocytes in the 
vasculature were counted using ImageJ and divided by the total retinal vascular area 
quantified using Adobe Photoshop. Normality of the dataset was confirmed with a 
D’Agostino & Pearson normality test with an alpha=0.05. This method was used in 
Chapter IV. 
 
VEGF enzyme-linked immunosorbent assay (ELISA) 
Human retinal astrocytes and human Müller cells were seeded in 6-well plates. 
At 70% confluency, cells were treated with vehicle (0.1% EtOH) or 5.0µM SKF-525A. 
Plates were either maintained in standard culture conditions (37°C, 5% CO2, 20.9% O2) 
or transferred to hypoxic conditions (37°C, 5% CO2, 0.1% O2). Cells were treated for 24 
hours, conditioned media were collected, and frozen at -80°C until use. Cells were 
collected using TrypLE (Invitrogen) and then lysed in 50µL RIPA buffer with protease 
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inhibitors. VEGF was measured with a VEGF colorimetric sandwich ELISA kit (R&D 
systems) and the normalized to total protein using a BCA assay (Pierce). This method 
was used in Chapter V. 
 
HRMEC proliferation 
HRMEC were seeded at 3 X 103 cells/well in a 96-well plate and cultured for 8 
hours in 10% FBS medium. Cells were then cultured in serum-reduced (0.5% FBS) 
medium for 12 hours. Cells were treated with 0.5% FBS medium containing vehicle 
(0.1% EtOH) or increasing concentrations of 11,12-EET (0.05µM – 0.5µM), recombinant 
human 25ng/ml VEGF vehicle (0.1% EtOH; Millipore) or VEGF containing increasing 
concentrations of SKF-525A (0.5µM – 5.0µM; ENZO Life Science). After treatment for 
24 hours, cells were labeled with BrdU for 12 hours. BrdU incorporation was quantified 
using a colormetric BrdU ELISA (Roche), according to the manufacturer’s protocol. 
Absorbance values were normalized to the 0.5% FBS vehicle for relative quantification. 
This method was used in Chapter V. 
 
HRMEC tube formation 
Twenty-four well tissue culture plates were coated with 300µL of growth factor 
reduced Matrigel® (Becton Dickenson). HRMEC were seeded at 2 X 104 cells/well on 
polymerized Matrigel®. Cells were treated with 0.5% FBS medium containing vehicle 
(0.1% EtOH), increasing concentrations of 11,12-EET (0.05µM – 0.5µM), 50ng/mL 
VEGF containing vehicle (0.1% EtOH), or increasing concentrations of SKF-525A 
(0.5µM – 5.0µM). After 8 hours of treatment, tubes were observed with an inverted 
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widefield fluorescence microscope (Nikon Eclipse Ti-E) and captured at 2x 
magnification. Capillary-like structures were measured to determine the mean tube 
length per field using ImageJ software (NIH), and these values were normalized to the 
0.5% FBS vehicle treatment group. The relative tube length per field of each treatment 
group is reported. This method was used in Chapter V. 
 
Rat model of oxygen-induced retinopathy (OIR) 
All animal procedures used in this study were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee and were performed in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. Within 8 hours after birth, litters of at least 14 Sprague-Dawley rat pups and 
their mothers (Charles Rivers Laboratories) were transferred to oxygen exposure 
chambers (BioSpherix), in which they were subjected to alternating 24 hour periods of 
50% and 10% oxygen for 14 days. On postnatal day 14, referred to as 14(0), the 
oxygen-exposed rats were returned to room air. They remained in room air for an 
additional six days, hereafter described as 14(1) through 14(6). Age-matched rat litters 
were also maintained in room air (RA) to serve as controls. This method was used in 
Chapter V. 
 
Retinal RNA isolation 
Retinas from 14(2) and room air day-matched controls (P16) were harvested by 
winkling directly into 150µL RNAlater® Solution (Ambion) and frozen at -20°C until use. 
Total RNA was isolated from tissue using RNA lysis buffer supplemented with β-
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mercaptoethanol using an RNeasy kit (Qiagen). A 5mm stainless steel bead (Qiagen) 
was added to each sample then samples were lysed using the TissueLyser LT (Qiagen) 
at 50Hz for 3 minutes. RNA isolation and quantification was performed as described 
above. This method was used in Chapter V. 
 
Quantification of retinal vascular area and neovascular area 
On 14(6), rats were sacrificed, their eyes enucleated and their retinas dissected 
in 4% paraformaldehyde. The retinal vasculature was stained for adenosine 
diphosphatase (ADPase; Sigma) activity.81 To accomplish this, isolated retinas were 
washed with tris buffer three times and once in tris buffer containing 0.1% Tween® 20 
(Sigma). Retinas were then incubated in ADPase at 37°C for 15-25 minutes, until 
retinas were white in color. Retinas were washed 3 times in tris buffer and then 
developed using ammonium sulfide. Retinas were washed 3 more times in tris buffer 
and then flatmounted. Images of ADPase-stained retinas were digitized, captured, and 
displayed at 20x magnification. For each retinal image, total retinal area, total vascular 
area, and pre-retinal vessel tuft area were outlined with an irregular polygon using 
Adobe photoshop. The pixels within the polygon were counted, and the total number of 
pixels from each polygon in a retina were pooled and converted to square millimeters. 
The vascular area measurements are shown as a percentage of the total retinal area. 
This method was used in Chapter V. 
 
 
 
	 44 
Retinal VEGF quantification 
OIR-exposed rats received intravitreal injections of vehicle (0.1% EtOH in PBS) 
or SKF-525A (5.0µM) on 14(1). Room air age-matched animals (P15) were injected with 
vehicle as a control. Retinas were collected on day 14(2), the peak day of retinal VEGF 
following oxygen exposure,84 sonicated in lysis buffer, and assayed for VEGF protein 
concentration with a colorimetric sandwich ELISA kit (R&D systems). The amount of 
VEGF (pg/mL) in retinas was normalized to total protein concentration (mg/mL) of 
retinal lysates using a BCA assay (Pierce). This method was used in Chapter V. 
 
Statistical analysis 
For Chapters III and IV, data were analyzed with the Prism software (GraphPad) 
using analysis of variance (ANOVA) with Fisher’s LSD post hoc analysis. Values of 
p<0.05 were considered statistically significant. 
For Chapter V, data were analyzed with commercial software (JMP; SAS 
Institute) using ANOVA with Student’s post hoc analysis. p<0.05 was considered 
statistically significant. 
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CHAPTER III 
 
MÜLLER CELL STIMULATION BY PALMITIC ACID AND ELEVATED GLUCOSE 
 
From: Capozzi M.E., Penn J.S. Palmitic Acid Induces Müller Cell Inflammation and is 
Potentiated by Co-treatment with Glucose. In review. 
 
Overview 
Based on the results of several clinical trials demonstrating that tight glycemic 
control slows the progression of DR, including the DCCT and UKPDS, hyperglycemia 
has been considered the driving cause of DR pathology. Owing to the long recognized 
reputation for glucose in DR, basic research has focused on elevated glucose in cell 
culture models to recapitulate mechanisms of DR. Yet, results from several clinical 
studies suggest glucose may not be the primary driver of DR, because overt 
hyperglycemia is not necessary for the development of pathology. For example, multiple 
case studies observed diabetic retinopathy pathology in patients with relatively normal 
glucose tolerance.230-232 Additional evidence comes from case studies of patients with 
bariatric surgery, in which there have been instances when retinopathy progressed, 
despite lowering of HbA1c.233 This provides the impetus to develop an understanding of 
non-glucose driven pathology in both in vitro and in vivo disease models for mechanistic 
understanding of DR pathogenesis. 
Recent studies have demonstrated a strong association between dyslipidemia 
and DR. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and 
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, the lipid 
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lowering drug, fenofibrate, delayed retinopathy progression, independent of glycemic 
control.16 In humans and animal models, diabetes increases fatty acid concentrations in 
systemic circulation and tissues, leading to inflammation, insulin resistance, and 
disease progression.234,235 Mounting evidence supports the use of fatty acids as a 
diabetes-relevant stimulus in non-ocular experimental contexts, but their use in the 
context of DR remains limited.95,102,193 Serum and tissue profiles from diabetic patients 
and experimental models of diabetes demonstrate that one saturated fatty acid, palmitic 
acid (PA), is elevated above others.192-194 Increased retinal levels of PA, as well as the 
unsaturated fatty acids, oleic acid (OA) and linoleic acid (LA), have been observed early 
in rodent models of diabetes.193,236 Furthermore, there is evidence of these fatty acids 
evoking inflammatory responses in retinal microvascular endothelial cells.95,237 These 
data suggest that elevated fatty acids may be causally linked to retinal inflammation 
occurring early in the pathogenesis of DR. 
An initial study in our lab (Appendix A) compared the effects of oleic acid and 
linoleic acid to those of elevated D-glucose to determine the relative consequences of 
these stimuli on the production of three DR-relevant inflammatory and angiogenic 
mediators; VEGF, IL-6, and IL-8. We used these stimuli to determine their effect on four 
human retinal cell types, three of which were primary (human Müller cells, human 
microvascular endothelial cells, and human retinal astrocytes), and the other of which 
was a transformed line of retinal pigmented epithelium (ARPE-19). From this study we 
identified that fatty acids serve as more potent stimulators of inflammatory mediator and 
growth factor production, and that this induction was specific to Müller cells. This 
observation served as the basis for the present study. 
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In the following experiments designed to determine the effect of CYP-derived 
epoxides in disease-relevant Müller cell cultures, we chose to use PA as the pathogenic 
stimulus for several reasons. First, PA treatment increased sEH protein levels in 
hepatocyte and adipocyte cultures.206 PA also induced TNFα, IL-1β and IL-6 up-
regulation in HepG2 cells, while CYP2J2 overexpression and 14,15-EET inhibited this 
induction.195,196 These examples demonstrate that PA is both diabetes-relevant and pro-
inflammatory, and suggest that its inflammatory properties are mitigated by EET/EDP 
treatment. Additionally, because it is saturated, our use of PA offers a distinct 
advantage over pro-inflammatory unsaturated fatty acids because it is not 
epoxygenated by CYPs,238 thus our epoxide measurements would not be confounded 
by contributions from metabolism of the stimulus. 
It is important to note that dyslipidemia occurs in the absence of diabetes, and 
hyperlipidemic patients do not have the same retinal pathology as that observed in DR. 
Thus there is potential for glucose to affect retinal cells, despite the limited effects on 
human primary cells that are unrelated to osmolarity (Appendix A). These 
considerations suggest that culture conditions using combinations of DR-relevant stimuli 
may be more relevant models to understand pathology in controlled in vitro 
experiments. Therefore, the first goal of these experiments was to compare PA- and D-
glucose treated primary human Müller cell cultures and to determine whether 
combination treatment further promoted DR-relevant pathways using whole 
transcriptome analysis for differential gene expression. 
Being that Müller cells are implicated as the main producers of inflammatory 
mediators, we next wanted to determine the effects of these inflammatory mediators on 
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their autocrine production, termed “auto-amplification.” Therefore, while the purpose of 
using D-glucose and PA in our initial studies is to recapitulate mechanisms involved in 
inflammatory initiation, in the next step of the study we used cytokines as stimuli to 
demonstrate their effects on amplification of inflammation in primary human Müller cells. 
We used the four inflammatory stimuli that are consistently elevated in the vitreous of 
patients with diabetic retinopathy; TNFα, IL-1β, IL-6, and IL-8. To assess their relative 
effects, we treated human Müller cells with each cytokine and used whole transcriptome 
analysis of differential expression to understand their comparative potencies as well as 
the full complement of activated factors. Thus, the overall goal of this chapter is to 
define relevant Müller cell conditions that are representative of both the initiation of 
inflammation as well as the amplification of inflammation by Müller cells in the diabetic 
retina. This platform will provide a basis for both mechanistic studies as well as 
assessment of therapeutic strategies in in vitro culture models. 
 
Results 
RNAseq Quality and Alignment 
In order to determine the effects of PA, D-glucose, and their combination on 
transcriptional changes in Müller cells, RNAseq was performed. The four experimental 
groups (2 samples of each) were treated as follows: LG/BSA (24 hours of L-glucose, 
followed by 24 hours of L-glucose plus BSA); LG/PA (24 hours of L-glucose, followed by 
24 hours of L-glucose plus PA); DG/BSA (24 hours of D-glucose, followed by 24 hours 
of D-glucose plus BSA); DG/PA (24 hours of D-glucose, followed by 24 hours of D-
glucose plus PA). The average read count was 11318908.38 reads per sample, 
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mapping on average 93.88% of the human genome (Table 4). The read counts were 
not statistically different between treatment groups using an ANOVA (p=0.2387). 
 
 
Table 4. Summary of reads mapping to the human genome using QC3. 
 
 
Figure 7. Transcripts with adjusted p-value<0.05 for A) LG/BSA vs. LG/PA, B) LG/BSA vs. 
DG/BSA, C) LG/PA vs. DG/PA.  
 
The Effect of PA Treatment on Human Müller Cell Gene Expression 
As shown in Figure 7A, 2540 hits were significantly changed as demonstrated by 
all three statistical tests (DESeq2, edgeR, and baySeq) between the LG/BSA and 
Sample Total Reads Mapped (%) 
LG/BSA1 11058763 93.38 
LG/BSA2 10249362 93.83 
LG/PA1 11245915 93.79 
LG/PA2 12642057 93.71 
DG/BSA1 11138539 94.01 
DG/BSA2 10804232 93.25 
DG/PA1 11808323 94.78 
DG/PA1 11604076 94.31 
Average 11318908.38 93.88 
A B C 
2540 
529 80 
54 
977 
1535 613 
4 
39 12 
24 
29 
328 71 
9 
20 13 
61 
10 
55 37 
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LG/PA groups. Of these, 740 were down-regulated while 1800 were up-regulated. The 
protein-coding genes with the largest log2fold changes are reported in Table 5. 
We then performed pathway analysis using only the significantly up-regulated 
genes to determine which biological pathways were enriched in our data set. Of these 
genes, 582 were identified in the KEGG database (Figure 8) and 173 were identified in 
the Biocarta database (Figure 9). Twenty-four pathways were significantly enriched by 
KEGG analysis and 11 pathways were significantly enriched by Biocarta analysis. Many 
interesting and relevant pathways were enriched, including inflammatory pathways 
linked to “NOD-like receptor signaling pathway” (19 hits) “RIG-I-like receptor signaling” 
(12 hits) and “Toll-like receptor signaling pathway” (15 hits). Additionally, in Biocarta 
pathway analysis, the “NFκB Signaling Pathway” (8 hits) and several associated NFκB 
pathway terms were enriched, in addition to “Signal transduction through IL1R” (8 hits). 
Additional DR-relevant pathways in the KEGG analysis include “Amino sugar and 
nucleotide sugar metabolism” (15 hits) “Neurotrophin signaling pathway” (22 hits), 
“MAPK signaling pathway” (36 hits), “PPAR signaling pathway” (13 hits), and 
“Apoptosis” (7 hits). MAPK signaling was also significantly enriched in Biocarta analysis.  
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Table 5. List of top 15 up-regulated genes (green) and down-regulated (red) genes in 
comparison of LG/BSA vs. LG/PA samples. Log2fold change is the average from all 
statistical tests. Adjusted p-value is reported from EdgeR analysis. 
Ensembl Gene ID Gene Target Log2fold change Adj p value 
ENSG00000081041 CXCL2 5.131169228 3.48E-121 
ENSG00000180535 BHLHA15 4.970842312 2.06E-107 
ENSG00000167861 HID1 4.556667723 4.04E-110 
ENSG00000078081 LAMP3 4.125085146 3.52E-55 
ENSG00000173110 HSPA6 4.097445282 6.88E-64 
ENSG00000167772 ANGPTL4 3.943015061 0 
ENSG00000004799 PDK4 3.804721573 1.73E-73 
ENSG00000163734 CXCL3 3.763486125 9.79E-57 
ENSG00000130487 KLHDC7B 3.660859835 4.54E-51 
ENSG00000162772 ATF3 3.640394145 0 
ENSG00000169429 CXCL8 3.546291509 4.45E-97 
ENSG00000147872 PLIN2 3.366381211 7.28E-273 
ENSG00000137491 SLCO2B1 3.359650884 1.19E-23 
ENSG00000099958 DERL3 2.985336774 9.33E-42 
ENSG00000133134 BEX2 2.952925525 4.57E-46 
ENSG00000180660 MAB21L1 -1.477045754 5.61E-19 
ENSG00000186847 KRT14 -1.497222046 7.37E-102 
ENSG00000167244 IGF2 -1.501273659 7.04E-114 
ENSG00000131095 GFAP -1.525215644 2.41E-13 
ENSG00000205221 VIT -1.564053796 1.28E-28 
ENSG00000105989 WNT2 -1.597706963 3.55E-46 
ENSG00000130592 LSP1 -1.628532041 4.50E-10 
ENSG00000137672 TRPC6 -1.629488495 3.81E-45 
ENSG00000179772 FOXS1 -1.669083989 1.64E-13 
ENSG00000163909 HEYL -1.703173713 3.48E-08 
ENSG00000104415 WISP1 -1.752999127 9.97E-21 
ENSG00000185585 OLFML2A -1.826404845 7.21E-51 
ENSG00000078401 EDN1 -1.96860795 5.77E-41 
ENSG00000163815 CLEC3B -2.078011452 3.05E-43 
ENSG00000106511 MEOX2 -2.333794203 2.36E-23 
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Figure 8. KEGG pathways enriched by PA-treatment alone. Pathway enrichment was 
determined using DAVID v6.7 with a p<0.05. 
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Figure 9. Biocarta pathways enriched by PA-treatment alone. Pathway enrichment was 
determined using DAVID v6.7 with a p<0.05. 
 
The Effect of D-glucose Treatment on Müller Cell Gene Expression 
 As shown in Figure 7B, using the stringency of all three statistical tests, only four 
genes were significantly altered between the LG/BSA and DG/BSA groups. Therefore, 
the 74 genes that were significant by any two statistical tests were used in pathway 
analysis in order to have a large enough population of hits. The top ten up-regulated 
and down-regulated hits from this group are reported in Table 6. Using this gene list, 
only the “Splicesome” pathway was significantly altered (6 hits; p=4.2E-5). 
0 0.5 1 1.5 2 2.5 
Acetylation and Deactylation of RelA in The 
NFkB activation by Nontypeable Hemophilus 
Signal transduction through IL1R 
The 4-1BB-dependent immune response 
Overview of telomerase protein component 
Erythropoietin mediated neuroprotection 
MAPKinase Signaling Pathway 
ATM Signaling Pathway 
CD40L Signaling Pathway 
Hypoxia and p53 in the Cardiovascular 
NF-kB Signaling Pathway 
-log10(p-value) 
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Table 6. List of top 10 up-regulated genes (green) and down-regulated (red) genes in 
comparison of LG/BSA vs. DG/BSA samples. Log2fold change is the average from all 
statistical tests. Adjusted p-value is reported from EdgeR analysis. 
 
 
The Effect of PA and D-glucose Combination Treatment on Müller Cell Gene 
Expression 
 We next compared the effect of PA on Müller cells after pre-treatment with D-
glucose (DG/BSA vs. DG/PA). While only 9 genes were significantly altered according 
to all three statistical tests, we used the 51 genes that were altered by any two statistical 
tests (Figure 7C) for analysis. In Table 7, the top 10 up-regulated and down-regulated 
genes are listed. Seventeen genes were up-regulated, and six of those were recognized 
Ensembl Gene ID Gene Target Log2fold change Adj p value 
ENSG00000134321 RSAD2 4.923508774 4.09E-08 
ENSG00000269483 AC006272.1 2.919487587 0.019466295 
ENSG00000164344 KLKB1 2.548189429 0.00071155 
ENSG00000111335 OAS2 2.17216683 7.02E-05 
ENSG00000089127 OAS1 2.168790961 4.62E-06 
ENSG00000183486 MX2 2.010356923 0.000545912 
ENSG00000137959 IFI44L 1.925914084 6.37E-08 
ENSG00000185885 IFITM1 1.304828318 0.003807034 
ENSG00000137965 IFI44 1.292143094 6.64E-10 
ENSG00000115267 IFIH1 1.147805314 0.001221134 
ENSG00000126458 RRAS -0.222524777 0.035308923 
ENSG00000175274 TP53I11 -0.228925103 0.038692229 
ENSG00000168159 RNF187 -0.235492533 0.044616825 
ENSG00000167244 IGF2 -0.247562395 0.026513466 
ENSG00000182809 CRIP2 -0.249868373 0.010900659 
ENSG00000183087 GA56 -0.268869012 0.007495434 
ENSG00000163017 ACTG2 -0.332161513 0.029633892 
ENSG00000070404 FSTL3 -0.344548454 0.005595595 
ENSG00000049540 ELN -0.359844309 0.021121557 
ENSG00000130176 CNN1 -0.410923384 0.007865768 
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by KEGG analysis. The only significantly enriched pathway was “Pathways in cancer” (5 
hits; p=8.1E-5) and within this pathway, genes specifically related to proliferation and 
angiogenesis were enriched. These included genes that encode: Cyclin D1, COX-2, 
MMP1, IL-8, and c-Jun. Because of their known relationships to diabetes pathology, we 
focused our validation on CXCL8 (IL8) and PTGS2. In Figure 10, we demonstrate PA 
induction of these targets, as well as a greater induction by pre-treatment with D-
glucose. PA treatment (LG/BSA vs. LG/PA) induced IL8 expression by 11.5-fold 
(p<0.0001) and PTGS2 expression by 3.5-fold (p<0.0001). Compared to PA-treated 
human Müller cells (LG/PA), D-glucose pre-treated cells (DG/PA) further induced IL8 
expression by 52.6% (p<0.0001) and PTGS2 expression by 24.2% (p=0.0440). The 
comparison of relative expression determined from qRT-PCR analysis to RNAseq 
analysis is shown in Appendix B. 
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Table 7. List of top 10 up-regulated genes (green) and down-regulated (red) genes in 
comparison of LG/PA vs. DG/PA samples. Bold/italicized genes indicate that these 
transcripts were also significantly altered in LG/BSA vs. LG/PA sample comparison. Log2fold 
change is the average from all statistical tests. Adjusted p-value is reported from EdgeR 
analysis. 
 
 
 
Ensembl Gene ID Gene Target Log2fold change Adj p value 
ENSG00000039600 SOX30 2.205032696 0.008276689 
ENSG00000159167 STC1 0.776414785 8.46E-07 
ENSG00000196611 MMP1 0.702045263 0.00040217 
ENSG00000169429 CXCL8 0.592836812 3.57E-07 
ENSG00000073756 PTGS2 0.528668486 1.66E-06 
ENSG00000122861 PLAU 0.421038355 0.004849631 
ENSG00000162772 ATF3 0.227905481 0.000343642 
ENSG00000128590 DNAJB9 0.226338735 0.000903843 
ENSG00000100934 SEC23A 0.221898127 0.046332084 
ENSG00000137831 UACA 0.195567228 0.000562227 
ENSG00000135480 KRT7 -0.386967885 0.033509088 
ENSG00000128510 CPA4 -0.418677262 6.12E-05 
ENSG00000171992 SYNPO -0.427503511 0.000329537 
ENSG00000130176 CNN1 -0.455594004 5.73E-05 
ENSG00000049540 ELN -0.460297597 0.000196689 
ENSG00000163431 LMOD1 -0.462317808 4.04E-07 
ENSG00000137124 ALDH1B1 -0.464431223 8.43E-07 
ENSG00000163017 ACTG2 -0.481167848 5.73E-05 
ENSG00000107796 ACTA2 -0.558187261 0.013391793 
ENSG00000149596 JPH2 -0.618904013 0.007443867 
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Figure 10. Validation of targets amplified in the DG/PA treatment group. Cells were 
acquired from 3 different donors, and treated the same as reported for the RNAseq analysis. (A) 
IL8 and (B) PTGS2 were induced by PA, and further amplified with pre-treatment of D-glucose. 
Data is reported as mean ± SEM (n=9). 
 
 
Validation of Müller Cell Phenotype 
As shown in Table 4, GFAP was one of the most highly down-regulated genes in 
response to PA treatment. This suggested that the treatment conditions may be causing 
the treated Müller cell cultures to de-differentiate. Thus, we verified that Müller cells did 
not de-differentiate in any of our culture conditions by assessing two common markers 
of Müller cell identity, GFAP and glutamine synthase (GS). As shown in Figure 11, 
Müller cell levels of GFAP and glutamine synthase (GS), as well as Müller cell 
morphology, remained constant in all treatment groups. 
	 58 
 
Figure 11. Validation of Müller cell phenotype across treatment groups. Mulller cells were 
treated as described for RNAseq analysis. GFAP (glial fibrallary activated protein) and GS 
glutamine synthase) were used for validation of Müller cell phenotype. DAPI was used to 
identify cell nuclei. All images were taken at 20x magnification. 
 
Cytokine Auto-amplification by Müller Cells 
 We next sought to determine the effects of cytokine-stimulated Müller cells on the 
production of these same cytokines, termed auto-amplification. In Figure 12, we 
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performed a time course using inflammatory mediators that are consistently elevated in 
the vitreous of patients with diabetic retinopathy: TNFα, IL-1β, IL-6, and IL-8. All 
treatments were administered at 1ng/ml. IL-1β was the most potent stimulus, inducing 
TNFα, IL-1β, and IL-6 significantly more than the other mediators at all time points 
assessed (Figure 12A-C). TNFα demonstrated similar potency to IL-1β for the induction 
of IL-8 (Figure 12D). 
 
 
 
Figure 12. Time course of inflammatory mediator effect on auto-amplification. Müller cells 
were treated with 1ng/ml of each inflammatory mediator (see graph key). Expression of (A) 
TNFα, (B) IL1β, (C) IL6, and (D) IL8 were compared to 18S expression as a control, and data 
are reported as the fold induction over the vehicle. Bars represent mean ± SD (n=3). 
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 RNAseq was performed using two samples from each treatment group, which 
were treated for 8 hours with 1ng/ml of the following human recombinant proteins: 
TNFα, IL-1β, IL-6, or IL-8. As shown in Figure 13, only TNFα and IL-1β induced 
significant alterations in Müller cell gene expression, as determined by using all three 
statistical tests (DESeq2, EdgeR, and baySeq). IL-1β had a larger effect than TNFα, 
because it differentially expressed 1477 gene targets while TNFα altered 212 gene 
targets. The top up-regulated and down-regulated genes are shown in Table 8 for TNFα 
and Table 9 for IL-1β. Interestingly, the list of most up-regulated genes are similar 
(CCL20, CSF2, CXCL8, and CXCL10) for TNFα and IL-1β, yet the size of the 
inflammatory response is greater in IL-1β treated cells. This is demonstrated by KEGG 
pathway analysis in Figure 14 and Figure 15; “Cytokine-cytokine receptor interaction” 
is the most significant pathway up-regulated by both TNFα and IL-1β, but the number of 
hits and significance in IL-1β-stimulated cells (42 hits; p=1.9E-20) is much greater than 
that for TNFα-stimulated cells (13 hits; p=2.4E-8). All pathways enriched by TNFα 
treatment (Figure 14) were also enriched by IL-1β (Figure 15). 
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Figure 13. Transcripts with adjusted p-value<0.05 for (A) TNFα-treated, (B) IL-1β-treated, 
(C) IL-6-treated, or (D) IL-8-treated Müller cells.  
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Table 8. List of top 10 up-regulated genes (green) and down-regulated (red) genes in 
comparison of vehicle vs. TNFα-treated samples. Log2fold change is the average from all 
statistical tests. Adjusted p-value is reported from EdgeR analysis. 
 
 
 
Ensembl Gene ID Gene Target Log2fold change Adj p value 
ENSG00000169245 CXCL10 8.026759425 0.0107210 
ENSG00000134321 RSAD2 5.595108551 0.0018596 
ENSG00000023445 BIRC3 5.53166577 0.0000267 
ENSG00000164400 CSF2 5.524018514 0.0165729 
ENSG00000169429 CXCL8 8.026759425 0.0181992 
ENSG00000204880 KRTAP4-8 5.595108551 0.0210578 
ENSG00000090339 ICAM1 5.53166577 0.0004370 
ENSG00000151572 ANO4 5.524018514 0.0055333 
ENSG00000183486 MX2 8.026759425 0.0047475 
ENSG00000115009 CCL20 5.595108551 0.0017661 
ENSG00000145681 HAPLN1 -4.442665891 0.0003414 
ENSG00000168079 SCARA5 -4.473338093 0.0038751 
ENSG00000131471 AOC3 -4.559672004 0.0053784 
ENSG00000174600 CMKLR1 -4.599861157 0.0000071 
ENSG00000149451 ADAM33 -4.626852708 0.0040869 
ENSG00000124920 MYRF -4.629950113 0.0001252 
ENSG00000162595 DIRAS3 -4.792761404 0.0000533 
ENSG00000091972 CD200 -4.913172953 0.0002284 
ENSG00000132622 HSPA12B -5.179285136 0.0025991 
ENSG00000034971 MYOC -7.660169261 0.0000376 
0 1 2 3 4 5 6 7 8 9 
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RIG-I-like receptor signaling pathway 
Chemokine signaling pathway 
NOD-like receptor signaling pathway 
Cytokine-cytokine receptor interaction 
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Figure 14. KEGG pathways enriched by TNFα treatment. Pathway enrichment was 
determined using DAVID with a p<0.05. 
 
 
Table 9. List of top 10 up-regulated genes (green) and down-regulated (red) genes in 
comparison of vehicle vs. IL-1β-treated samples. Log2fold change is the average from all 
statistical tests. Adjusted p-value is reported from EdgeR analysis. 
 
Ensembl Gene ID Gene Target Log2fold change Adj p value 
ENSG00000108342 CSF3 10.4153456 0 
ENSG00000007908 SELE 9.50836945 9.29E-285 
ENSG00000163734 CXCL3 8.970547385 0 
ENSG00000163739 CXCL1 8.756812978 0 
ENSG00000081041 CXCL2 8.557509753 0 
ENSG00000115009 CCL20 8.322086144 0 
ENSG00000169429 CXCL8 8.055145731 6.47E-212 
ENSG00000164400 CSF2 7.767223895 6.87E-230 
ENSG00000125538 IL1B 7.113063114 0 
ENSG00000169245 CXCL10 6.877020604 2.35E-68 
ENSG00000143850 PLEKHA6 -2.347383947 0 
ENSG00000111087 GLI1 -2.387906314 0.00481442 
ENSG00000143631 FLG -2.438031045 0 
ENSG00000168497 SDPR -2.471388158 0 
ENSG00000144229 THSD7B -2.525244528 0.002870717 
ENSG00000196196 HRCT1 -2.527825526 6.75E-14 
ENSG00000162630 B3GALT2 -2.55306345 9.83E-06 
ENSG00000125378 BMP4 -2.773861711 0 
ENSG00000181072 CHRM2 -2.783228974 0 
ENSG00000134215 VAV3 -3.351086987 3.15E-09 
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Figure 15. KEGG pathways enriched by IL-1β treatment. Pathway enrichment was 
determined using DAVID with a p<0.05. 
 
Conclusions 
Pathways Regulated by PA and DG/PA 
The most important finding from this study is that elevated glucose, interacting 
with the saturated fatty acid, PA, generates a more robust induction of diabetes-relevant 
gene expression than either stimulus alone. A particularly important finding was that 
glucose alone had little to no effect on Müller cells, despite it being the most commonly 
used stimulus for DR basic research. These results are important for the interpretation 
of several clinical studies. First, our findings support the results of the FIELD and 
ACCORD studies, which demonstrated that modulation of dyslipidemia, independent of 
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glucose control, reduced the need for laser treatment of DR.16,17 Furthermore, our 
results suggest that the interpretation of the findings in the DCCT and UKPDS trials, in 
which glycemic control was significantly associated with DR progression,12,13 be 
considered in a broader context because several metabolic changes are associated 
with glycemic control. Yet, many in vitro studies in the DR field use glucose as a 
diabetes-relevant stimulus due to the results of these clinical studies. Intensive glycemic 
control is achieved by insulin treatment, and several metabolic changes occur with 
insulin therapy in diabetics. Thus, the data in the present study, in which conventional 
elevated glucose conditions yielded no response from Müller cells, demonstrate the 
need for a more careful consideration of metabolic changes in DR basic research, 
beyond glucose alone. 
Several disease relevant targets were identified after treatment of human Müller 
cells with PA alone, while no notable targets were detected with D-glucose treatment 
alone. Of the most highly expressed genes stimulated by PA, three are from the C-X-C 
family of chemokines (CXCL2, CXCL3, and CXCL8). These chemokines all signal 
through the CXCR2 receptor, while CXCL8 also signals through the CXCR1 receptor. 
These ligands have been implicated in neutrophil migration and chemotaxis.239 While 
virtually nothing is known regarding CXCL2 and CXCL3 in diabetic retinopathy, CXCL8 
(also called IL-8) has been found to be elevated in the vitreous of diabetic retinopathy 
patients.240-242 Other interesting targets on this list include PLIN2 and ANGPTL4, which 
are well-characterized targets of PPARβ/δ signaling. This signaling pathway was also 
significantly enriched with PA treatment (Figure 8). Our lab has demonstrated that 
PPARβ/δ signaling is involved in several pathological steps of DR, including TNFα-
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induced retinal vascular leukostasis (Capozzi et al. in review), VEGF-induced vascular 
permeability,243 and retinal angiogenesis.244 Furthermore, ANGPTL4 has recently been 
demonstrated to be an important factor in diabetes-induced angiogenesis in PDR.245,246 
These data further demonstrate that PA is a useful stimulus for understanding elements 
of DR pathogenesis in retinal cell culture, because PA-stimulated cultures faithfully 
recapitulate important pathogenic endpoints observed in the diabetic retina. 
In PA treated cells, we also observed significant enrichment of the neurotrophin 
pathway. Of the identified targets, nerve growth factor (NGF) was the only ligand up-
regulated in this pathway. Notably, NGF is increased in the diabetic rat retina and in 
tears of diabetic patients.247-249 While NGF is predominantly involved in neuronal cell 
survival, it is expressed as proNGF and requires cleavage to exert its pro-survival 
activity.248 ProNGF signals through a separate receptor, p75NTR, which has been found 
to cause neuronal cell death and vascular permeability in the retina.250 In diabetic 
retinopathy, the ratio of proNGF/NGF is increased, suggesting a greater pro-
inflammatory and pro-apoptotic activity.248 While further work should be directed at 
understanding the relative amount of proNGF and NGF in PA-treated Müller cell 
cultures, our data recapitulates the up-regulation of NGF transcription that is observed 
in DR models and patients. 
 The most exciting results from this study is that D-glucose pre-treatment of 
human Müller cells amplifies the response to PA, while exerting few effects alone. 
Compared to PA treatment, PA co-treatment with D-glucose further stimulated a limited 
subset of targets, predominantly involved in inflammation and angiogenesis. Two of 
these targets, IL8 (or CXCL8) and PTGS2, were verified to be induced by PA and 
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further amplified by co-treatment with D-glucose (Figure 10). COX-2 (PTGS2 product) 
is an inducible enzyme involved in prostaglandin synthesis, and is a target of non-
steroidal anti-inflammatory drugs (NSAIDs). NSAIDs and COX-2 inhibitors have been 
shown to reduce retinal leukostasis and vascular permeability in diabetic rodents, 
independent of VEGF levels.118 COX-2 is also involved in the late stages of disease, 
and its inhibition prevents the development of ischemia-induced 
neovascularization.251,252 Additionally, PGE2, a downstream product of COX-2 
metabolism, is up-regulated in the vitreous of diabetic patients with PDR.253 Our lab has 
previously shown that PGE2 can signal via the EP4 receptor to stimulate retinal 
angiogenesis.254 Therefore, our data further validated COX-2 as a potential drug target. 
More importantly, our data demonstrated the utility of combination treatment of PA and 
D-glucose for understanding DR pathology in Müller cells. 
 Interestingly, we identified several angiogenic factors up-regulated by PA and/or 
DG/PA treatment, including but not limited to: CXCL8, ANGPTL4, COX-2, and VEGF. 
Notably, these have all been shown to be hypoxia-inducible factors, and in fact, 
“hypoxia and p53 in the cardiovascular system” was an enriched pathway by Biocarta 
analysis (Figure 9). Yet, we observed their induction in the absence of hypoxia. This 
suggests that metabolic changes independent of hypoxia-induced growth factor 
induction may mediate the progression from early to late angiogenic stages of DR. This 
finding is supported by a recent study, which demonstrated that altered lipid and 
glucose usage in Vldlr-/- animals drives retinal Vegfa expression and subsequent 
neovascularization in the absence of hypoxia.255 This VEGF up-regulation was 
observed in photoreceptors exposed to conditions of abundant fatty acids, such as 
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excess palmitic acid in culture.255 The present study suggests that excessive fatty acids 
may also affect other highly metabolic cell types in the retina, such as the Müller cells.  
Our results from DG/PA-treated human primary Müller cells may have greater 
mechanistic relevance to early glial changes associated with DR for several reasons. 
First, our use of human-derived cells allowed for analysis of targets relevant to the 
human disease. For example, one of the targets that was most highly amplified in 
LG/PA and was more amplified in DG/PA was IL-8. IL-8 is well characterized for its role 
in leukostasis, and it is found in high levels in the vitreous of diabetic patients.240,241 
However, it is not expressed in mice. Thus, its importance to the disease process is 
largely undefined because of its lack of identification in studies using rodent-derived 
cells or rodent models of diabetes. This supports our practice of using human-derived 
cells. Another important aspect of the study is the inclusion of an appropriate osmotic 
control. As shown in Appendix A, VEGF was induced similarly when Müller cells were 
treated with either L-glucose or D-glucose, suggesting that osmotic stress, and not 
signaling mechanisms, is the main inducer of VEGF in these cells. Yet, many 
researchers claim that elevated glucose stimulates VEGF in various Müller cell lines 
without using this critical osmotic control. Therefore, while our results are consistent 
with the literature that shows D-glucose stimulation of VEGF production, it is likely that 
these changes are a result of osmotic stress alone. A recent study clearly demonstrated 
the role of osmotic stress in microvascular endothelial cell induction of COX-2.256 The 
potential role of osmotic induction of COX-2 was controlled for in our study because an 
osmotic stress was applied in all treatment groups. Lastly, the use of human primary 
Müller cells may be more relevant to understanding mechanisms of DR pathogenesis. 
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Virtually all studies assessing glucose-induced behaviors in the literature use either 
transformed cell lines (rMC-1 or MIO-MI) or rodent-derived Müller cells.257-262 In 
preliminary studies, our lab has demonstrated that constitutive VEGF expression levels 
in the human transformed cell line, MIO-MI, are similar to hypoxia-induced VEGF 
expression levels in primary human Müller cells, suggesting that these cells are not 
appropriate for experiments of this type. Taken together, due to the technical limitations 
of many other studies, we believe the results of this study highlight more relevant 
targets and induction profiles for the human disease. 
 
Pathways Regulated by Inflammatory Cytokines 
In this study, only TNFα and IL-1β were able to stimulate inflammation in human 
retinal Müller cells. IL-1β was the more potent stimulus compared to TNFα, because it 
altered more transcripts (1477 vs. 212; Figure 13), it significantly enriched more 
pathways (15 vs. 5; Figures 14 and 15) and the significance of enrichment for 
pathways altered by both treatment groups was greater for IL-1β (Figures 14 and 15). 
This suggests that IL-1β is a more potent regulator of Müller cell behavior, and thus its 
neutralization or inhibition of its downstream signaling may be more important to 
disease progression than other inflammatory mediators that are elevated in DR. 
Notably, of the 10 most up-regulated targets for each treatment, four were the 
same for both TNFα and IL-1β (CCL20, CSF2, CXCL8, and CXCL10; Table 8 and 9). 
All of these targets encode chemokines that are involved in leukocyte recruitment and 
are altered in the retina of experimental diabetes models and/or vitreous of patients with 
diabetic retinopathy.240-242,263 Interestingly, one of the most significantly altered genes by 
	 70 
IL-1β treatment is the gene that encodes IL-1β. This “auto-amplification” has been 
hypothesized in the diabetic retina, and is suggested as an initial cause as well as 
propagator of Müller cell and retinal endothelial cell activation.93 Our data supports the 
hypothesis that IL-1β auto-stimulation contributes to the chronic neuroinflammation 
observed in DR. Thus, inhibition of IL-1β induction could prevent a cycle of amplified 
cytokine production by Müller glia.  
We were surprised to find that IL-8 treatment did not yield any significant 
alterations of gene expression in primary human Müller cells. Rabbit retinal Müller cells 
and the transformed cell line MIO-MI have previously been shown to have 
immunoreactivity for the IL-8 receptors, CXCR1 and CXCR2.264 Further work is 
necessary to verify receptor expression in primary human Müller cells. However, 
CXCR2 is highly expressed in circulating leukocytes, and thus it is more likely that 
Müller cell production of IL-8, which was on the list of most highly expressed genes in 
several RNAseq datasets in this Chapter (Tables 5, 7, 8, and 9), is of greater functional 
significance for its recruitment of circulating cells to the retina than for the direct 
propagation of Müller cell inflammation. 
One caveat to this study is that all cytokines were used in equal doses to assess 
potency, however these doses do not necessarily reflect the physiologic ratios in situ. 
For instance, in response to PA, IL-6 and IL-8 levels are more significantly up-regulated 
than IL-1β or TNFα. Therefore, fold differences between these inflammatory mediators 
in relevant culture or in vivo conditions may be different, and thus direct comparison of 
potency may be irrelevant. However, the expression levels of TNFα, IL1β, IL6, or IL8 will 
vastly differ based on cell type, culture conditions, levels from different disease models, 
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or other conditions used for study. Thus, we think this direct comparison of potencies, 
evidenced by using all mediators at the same concentrations, is advantageous for 
determining appropriate culture conditions to study mechanisms of DR pathology and 
potential therapeutics. Future studies should be designed to compare the relevant 
concentrations of these inflammatory mediators from conditioned medium or soluble 
fractions of vitreous to learn more about their roles in disease pathology. 
 
Implications of Transcriptome-wide Analysis for Study of Epoxides in Müller Cell 
Inflammation 
 After querying the lists of differentially expressed genes, only one CYP 
epoxygenase was significantly altered (adjusted p<0.05 in all three statistical tests) in 
any of the datasets; CYP2S1 was down-regulated by 86.2% after TNFα treatment for 8 
hours. Soluble epoxide hydrolase (Ephx2) was not significantly changed in any of the 
datasets. Though these data must be confirmed via assessment of enzyme activity, the 
results of our RNAseq suggest that epoxide therapy may be most efficacious against 
TNFα-induced inflammation in Müller cells. Consistent with the lack of CYP/sEH 
changes observed in PA-treated Müller cell cultures, PA did not alter the levels of 
epoxides in culture media in preliminary studies (Appendix C). Future work should 
focus on validating the effects of these diabetes-relevant culture conditions on the CYP 
and sEH enzyme levels and their activities. 
 Despite the relative lack of changes to the epoxide-regulating enzymes, the 
RNAseq datasets still suggest that EET/EDP therapy may be beneficial for any of the 
treatment conditions described. Based on our pathway analysis, several enriched 
	 72 
pathways are modulated by epoxides, including the PPAR pathway, NFκB-related 
signaling pathways, cytokine signaling, and apoptosis. Thus, future studies in the lab 
should be focused on how exogenous addition of EET, EDP, and/or sEH inhibition can 
modulate the induction of these targets by PA-, DG/PA-, IL-1β-, or TNFα-treated Müller 
cells. 
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CHAPTER IV 
 
EFFECT OF EPOXIDES ON TNFα-INDUCED RETINAL VASCULAR INFLAMMATION 
 
From: Capozzi M.E., Hammer, S.S., McCollum, G.W., Penn J.S. (2016) Epoxygenated 
Fatty Acids Inhibit Retinal Vascular Inflammation. Sci. Rep. 6, 39211. 
 
Overview 
 Several pro-inflammatory cytokines are elevated in the vitreous of diabetic 
patients, and these cytokines drive the early stages of disease. Of the primary cytokines 
selected from the previous chapter (TNFα, IL-1β, IL-6, and IL-8), TNFα is the most 
potent inducer of endothelial cell adhesion molecules and leukocyte adhesion to 
endothelial cell monolayers (Appendix D). There is ample evidence supporting TNFα 
as a diabetes-relevant stimulator of retinal inflammation. For example, elevated TNFα 
levels in the serum and vitreous of DR patients correlate with disease progression and 
morbidity.86,89,91,265 Furthermore, deletion of TNFα inhibited diabetes-induced 
leukostasis and retinal vascular leakage in mice.266 TNFα induces the expression of the 
leukocyte adhesion proteins vascular cell adhesion molecule-1 (VCAM1) and 
intercellular adhesion molecule-1 (ICAM1) in human retinal endothelial cells.76,267 Both 
function in the firm adherence of leukocytes facilitating their immobilization; a process 
referred to as leukostasis. The pathologic implications of retinal leukostasis were 
discussed in Chapter I. Briefly, when leukocytes adhere to the luminal surface of the 
retinal capillary endothelium, they are believed to cause the formation of vaso-occlusive 
thrombi that can obstruct blood flow, causing oxygen starvation and subsequent 
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capillary death. The death of retinal capillaries is a pivotal point in DR pathogenesis 
because it results in the formation of focal areas of retinal ischemia that become 
hypoxic. In response to hypoxia, the retina elaborates vascular endothelial cell grow 
factor (VEGF) and other growth factors that promote the onset of PDR along with its 
associated vision-threatening morbidities. Adherent leukocytes also secrete noxious 
stimuli, such as reactive oxygen species and inflammatory cytokines, which further 
contribute to inflammation, blood-retina barrier breakdown, retinal vaso-regression, and 
edema; all hallmarks of DR.121,268-270 Interestingly, studies have shown that genetic 
deletion or antibody blockade of ICAM-1 has beneficial effects on multiple pathogenic 
outcomes in experimental DR, including leukostasis and vascular permeability.117,121 
Diabetes is known to alter multiple pathways involved in endogenous fatty acid 
metabolism. Tissues can metabolize fatty acids to biologically active lipid mediators 
through the cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 
epoxygenase (CYP) pathways. While COX, LOX, and their products have received 
considerable attention in the diabetic retina,118,123,271-277 relatively little is known about 
the role of retinal CYP-derived lipid mediators. CYP-derived epoxides, and particularly 
the EET products, are known to exert a number of potent anti-inflammatory activities in 
diverse vasculature beds, including reduced VCAM1 and ICAM1 expression.103,143,146,278 
Soluble epoxide hydrolase represents a rational and promising therapeutic target to 
inhibit these adhesion molecules because its inhibition elevates levels of anti-
inflammatory epoxides. Thus, sEH inhibition has been the objective of multiple clinical 
trials in diabetes-related pathology.222-226 Notably, sEH inhibition has not yet been 
examined as a treatment for retinal disease.  
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Reduced levels of EET are observed in the vitreous of patients with NPDR and 
PDR,89 and the decreased epoxide levels may be permissive for increased retinal 
inflammation. Accordingly, therapeutic interventions that raise EET and EDP levels may 
be expected to ameliorate DR inflammation; however, these approaches have not been 
assessed. Based on these considerations, in the present study we hypothesized that 
treatment of primary human retinal microvascular endothelial cells (HRMEC) with a DR-
relevant inflammatory cytokine, TNFα, would decrease epoxide production, limiting their 
anti-inflammatory effects. Conversely, elevation of epoxide levels by their exogenous 
addition as well as sEH inhibition may block cytokine-induced inflammatory events in 
HRMEC, providing a basis for a viable therapeutic strategy to inhibit the retinal vascular 
inflammation that is observed at the onset of diabetic retinopathy. 
 
Results 
TNFα Decreases Epoxyeicosatrienoic Acid Levels in HRMEC-Conditioned Medium  
TNFα has previously been shown to alter levels of the cytochrome P450 
enzymes that produce epoxygenated fatty acids,186,279 however any effects of TNFα on 
EET or EDP production by endothelial cells has not been determined. To investigate 
these effects, HRMEC were treated with TNFα followed by treatment with substrate (AA 
and DHA; 10µM each), and epoxide levels were measured in the conditioned medium. 
Although no specific regioisomer was significantly decreased, the sum of all EET 
regioisomers was significantly lowered by 37.6% (p<0.001). While not significant, total 
EDP was lowered by 26.5% (Figure 16).  
 
	 76 
 
Figure 16. The effect of TNFα on epoxygenated fatty acid levels. HRMEC were treated with 
vehicle or TNFα (1ng/ml), arachidonic acid and docosahexaenoic acid substrates were 
provided, and the level of their epoxygenated products was measured in the conditioned media 
by LC-MS/MS. These data are normalized to the total protein of the cell lysates. Each bar 
represents the mean ± SEM (n=8 for EET measurements; n=9 for EDP measurements). 
 
11,12-EET or 19,20-EDP in combination with AUDA Inhibit, and 19,20-DHDP Promotes, 
TNFα-induced VCAM1 and ICAM1 Expression  
We investigated the effects of the exogenous addition of epoxides or sEH 
inhibition on TNFα-induced inflammation in HRMEC cultures. sEH activity was inhibited 
using 12-(3-adamantane-1-yl-ureido)-dodecanoic acid (AUDA); AUDA stabilizes both 
exogenous and endogenous EET and EDP by blocking hydrolysis of the epoxides to 
diols, extending their biological half-lives to presumably potentiate any biological effects. 
In Figure 17, we verified that hydrolysis was reduced in HRMEC cultures following 
AUDA treatment. We treated HRMEC cultures with exogenous 11,12-EET, 19,20-EDP, 
AUDA, or the EET and EDP diols, 11,12-DHET and 19,20-DHDP and assessed there 
effects on TNFα-induced VCAM1 and ICAM1 in HRMEC. The concentrations of the 
epoxides (0.5µM) or the sEH inhibitor AUDA (10µM) were determined from preliminary 
studies and fall within typical ranges used in the literature.146,172,280-283 As shown in 
Figure 18A, 11,12-EET significantly reduced (49.6%; p=0.0001) and 19,20-DHDP 
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increased (84.6%; p=0.001) TNFα-induced VCAM1 expression, while the other 
treatments yielded no significant effect on VCAM1. None of these treatments had an 
effect on ICAM1 expression, with the exception of 19,20-DHDP, which increased TNFα-
induced ICAM1 expression by 54.5% (p=0.0001).  
Next, we treated TNFα-stimulated HRMEC with combinations of 11,12-EET or 
19,20-EDP and AUDA and assessed any effects on VCAM1 and ICAM1 expression. As 
shown in Figure 18B, 11,12-EET plus AUDA inhibited VCAM1 by 32.5% (p=0.0001) 
and ICAM1 by 31.9% (p=0.0001). Similarly, 19,20-EDP plus AUDA inhibited VCAM1 by 
37% (p=0.0001) and ICAM1 by 20.7% (p=0.0027). 
 
 
Figure 17. AUDA alters EET-to-DHET ratios. To verify inhibition of epoxide hydrolysis by 
AUDA, EET:DHET ratio was measured in AUDA-treated HRMEC. EET:DHET for each isomer 
was increased, but only the ratio of the 11,12 regioisomer was significantly increased. Each bar 
represents mean ± SD (n=3). 
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Figure 18. The effect of 11,12-EET, 19,20-EDP, AUDA, or the corresponding diols on 
TNFα-induced adhesion molecule expression. HRMEC were treated with TNFα in the 
presence or absence of (A) 11,12-EET (0.5 µM), 19,20-EDP (0.5 µM), AUDA (10 µM), 11,12-
DHET (0.5 µM), or 19,20-DHDP (0.5 µM); or (B) combinations of 11,12-EET or 19,20-EDP with 
AUDA. Expression of VCAM1 and ICAM-1 was assessed by qRT-PCR analysis. Each bar 
represents the mean ± SEM (A: n=6; B: n=12). 
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To further validate the effect of 11,12-EET or 19,20-EDP in combination with 
AUDA, VCAM-1 and ICAM-1 protein levels were assessed. HRMEC were treated with 
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VCAM-1 and ICAM-1 levels were determined by immunoblot analysis. As shown in 
Figure 19, 11,12-EET plus AUDA inhibited both VCAM-1 and ICAM-1 levels by 27.5% 
(p=0.0007) and 44.5% (p=0.0004), respectively. 19,20-EDP plus AUDA performed 
similarly, inhibiting VCAM-1 by 29.2% (p=0.0011) and ICAM-1 by 30.3% (p=0.005). 
 
 
Figure 19. The effect of 11,12-EET or 19,20-EDP plus sEH inhibition on TNFα-induced 
VCAM-1 and ICAM-1 protein levels. (A) Representative blots from HRMEC treated with TNFα 
in the presence or absence of 11,12-EET (0.5 µM) or 19,20-EDP (0.5 µM) with AUDA (10 µM); 
and (B) quantification of 3 individual blots. Each bar represents the mean ± SEM (n=3). 
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We performed leukocyte adhesion assays to determine how EET- and EDP-
dependent VCAM-1 and ICAM-1 expression and protein levels affect TNFα-induced 
leukocyte adhesion. HRMEC monolayers were cultured in a parallel plate flow chamber 
and treated with TNFα in the presence or absence of 11,12-EET or 19,20-EDP plus 
AUDA for 4 hours. Untreated peripheral blood mononuclear cells (PBMC) were flowed 
over the monolayers and adhesion was measured. As shown in Figure 20, TNFα 
induced PBMC adhesion by 4.3-fold; 11,12-EET or 19,20-EDP plus AUDA inhibited this 
induction by 47.6% (p=0.0268) and 49.9% (p=0.0436), respectively. 
 
 
Figure 20. The effect of 11,12-EET or 19,20-EDP plus AUDA on TNFα-induced leukocyte 
adhesion to HRMEC monolayers. HRMEC monolayers were treated TNFα in the presence or 
absence of 11,12-EET (0.5 µM) or 19,20-EDP (0.5 µM) with AUDA (10 µM), and PBMC were 
then flowed over the treated monolayers in a parallel plate flow chamber. Each bar represents 
the mean ± SEM (vehicle: n=8; TNFα: n=9; 11,12-EET + AUDA: n=6; 19,20-EDP: n=4). 
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11,12-EET or 19,20-EDP with sEH Inhibition Reduces TNFα-induced NFκB Activity  
In various macrovascular endothelial cell types, 11,12-EET exerts its anti-
inflammatory effects by preventing IκBα degradation and subsequent NFκB 
translocation.146,172,173 To assess whether 11,12-EET and 19,20-EDP are working 
through this mechanism, NFκB activity was measured using a promoter assay. HRMEC 
were transfected with a luciferase promoter construct and treated with TNFα in the 
presence or absence of 11,12-EET or 19,20-EDP plus AUDA. As shown in Figure 21A, 
11,12-EET or 19,20-EDP plus AUDA inhibited TNFα-induced NFκB activation by 24.6% 
(p=0.0342) and 28% (p=0.0161), respectively. However, this inhibition was not via a 
direct effect on IκBα degradation (Figure 21B). 
 
 
Figure 21. The effect of 11,12-EET or 19,20-EDP plus AUDA on TNFα-induced NFκB 
activation. (A) HRMEC were transfected with luciferase constructs and treated with TNFα in the 
presence or absence of 11,12-EET (0.5µM) or 19,20-EDP (0.5µM) with AUDA (10µM). NFκB 
activity was determined by measuring the ratio of firefly-to-Renilla luciferase. Each bar 
represents the mean ± SEM (n=20). (B) Representative blot of IκBα, with β-Actin as a loading 
control. Treatment with 11,12-EET or 19,20-EDP with AUDA inhibition did not prevent TNFα-
induced IκBα degradation. 
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11,12-EET or 19,20-EDP with sEH Inhibition Mitigates TNFα-induced Retinal 
Leukostasis 
For proof of concept in vivo, we assessed the effects of elevating EET or EDP 
levels on an acute mouse model of retinal inflammation. C57BL/6J mice received 
intravitreal injections of TNFα in the presence or absence of 11,12-EET or 19,20-EDP 
plus AUDA; adherence of leukocytes to retinal vessels was analyzed six hours post-
injection. As shown in Figure 22, TNFα induced retinal vascular leukocyte adherence 
by 87.3% (p=0.0024), similarly to previous reports.76 Co-treatment with either 11,12-
EET or 19,20-EDP plus AUDA completely mitigated the TNFα-induced adherence of 
leukocytes in retinal vessels (p=0.0241 and p=0.0007, respectively). 
 
 
Figure 22. The effect of 11,12-EET or 19,20-EDP plus AUDA on TNFα-induced retinal 
leukostasis. Mice were injected intravitreally with 50 ng/ml TNFα in the presence or absence of 
11,12-EET (0.5µM) or 19,20-EDP (0.5µM) with AUDA (10µM). (A) Representative images of 
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retinal flatmounts with concanavalin-A perfusion; yellow arrows indicate adhered leukocytes; (B) 
quantification of adherent leukocytes normalized to retinal area. Bars represent mean ± SD 
(vehicle: n=8; TNFα: n=16; 11,12-EET + AUDA: n=4; 19,20-EDP + AUDA: n=12). 
 
Conclusions 
Our data demonstrated for the first time that 11,12-EET and 19,20-EDP are 
similarly efficacious against TNFα-induced vascular inflammation. While EET is well 
established as an anti-inflammatory lipid that inhibits the induction of leukocyte 
adhesion molecules in various endothelial cell types,103,146,172,278 these activities have 
never been demonstrated for EDP. Interestingly, the EET and EDP precursors, AA and 
DHA respectively, have opposing effects on leukocyte adhesion molecule expression in 
retinal endothelial cells. AA increases VCAM-1 and ICAM-1 levels,237 while DHA 
decreases TNFα-induced VCAM-1 and ICAM-1 levels.284,285 In the present study, we 
demonstrated that these opposing roles are no longer observed when using the 
epoxygenated products, 11,12-EET and 19,20-EDP. It is important to note that the rate 
of epoxide biosynthesis is limited by substrate availability.286 Though DHA is abundant 
in the retina, this is almost exclusively due to enrichment in the retinal photoreceptor 
outer segment membranes. In the retinal vasculature, AA and DHA are found in equal 
amounts,131 suggesting that both substrates, and therefore their products, would likely 
be found in similar levels at the site of epoxide generation in the vasculature. Thus, both 
AA- and DHA-derived epoxides may contribute similarly to retinal vascular homeostasis, 
particularly relating to inflammation. 
In this study, we used only one of the four EET regioisomers (11,12-EET) and 
one of the five EDP regioisomers (19,20-EDP). 11,12-EET was used due to its high 
relative abundance in retinal endothelial cell cultures (Figure 16) and retinal tissue,132 
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as well as its proven anti-inflammatory capacity compared to other regioisomers.146,171 
These data suggest that changes in the levels of 11,12-EET may be highly biologically 
relevant in the retina. Similarly, 19,20-EDP is the most abundant DHA-derived epoxide 
product in the retina.132,138,151 19,20-EDP is the least efficiently metabolized sEH 
substrate of the DHA-derived epoxides, suggesting that therapeutic levels may be more 
easily achieved compared to the other regioisomers.138  
While diol products are often inactive in the vasculature, in the retina, the 19,20-
DHDP has been shown to promote developmental angiogenesis.132 In the present 
study, we demonstrate a pro-inflammatory activity for this diol product in retinal 
endothelial cells. This finding further argues for the use of sEH inhibition as an 
efficacious therapeutic strategy because it would not only promote elevated levels of 
anti-inflammatory epoxygenated fatty acids, but also reduce the production of their pro-
inflammatory diol products. 
The sEH enzyme is highly expressed in the endothelium throughout a variety of 
tissue beds,280,287-290 and we demonstrated its activity in HRMEC cultures (Figure 17). 
However, in the developing mouse retina, sEH immunoreactivity did not co-localize with 
the vascular lectin stain, isolectin GS-IB4 from Griffonia simplicifolia.132 Soluble epoxide 
hydrolase is constitutively expressed and inducible by systemic factors. In diabetes and 
obesity, which is associated with a chronic systemic inflammation, sEH levels are 
elevated, and their levels are responsive to insulin therapy.205,291 Furthermore, 
endothelial cell activation with homocysteine, a systemic factor associated with diabetic 
retinopathy,190 induced sEH expression and protein levels as well as VCAM-1 
expression, while sEH inhibition reduced homocysteine-induced VCAM-1 induction.207 
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Another diabetes-relevant stimulus, angiotensin II, induced sEH levels via c-Jun binding 
to SP-1 sites in the 5’-flanking region.289,292 TNFα has been shown to activate c-Jun in 
endothelial cells,293 yet its direct effect on sEH expression has not been assessed. 
Thus, TNFα-induced inflammation may alter EET/EDP levels in our HRMEC cultures via 
increased sEH expression and activity. 
While AUDA potently inhibits sEH activity, as demonstrated in Figure 17, it is 
important to note that it can have off-target effects related to the end points examined in 
this study. For instance, Fang et al. (2005) demonstrated weak PPARα agonism with 
AUDA treatment.294 However, in the present study AUDA does not recapitulate PPARα 
agonism, because PPARα activation is efficacious against TNFα-induced vascular 
inflammation,295 but AUDA alone did not exhibit any effect on these endpoints (Figure 
18 and Appendix E). Therefore, in the context of this study, we believe that AUDA is 
functioning by sEH inhibition, because it is only efficacious when paired with exogenous 
epoxides. 
TNFα-induced retinal leukostasis was adapted for use in this study as a model of 
low-grade chronic inflammation related to DR, as reported previously.76 We chose to 
administer a dose of TNFα (50pg) to the vitreous cavity that was based on preliminary 
dose response profiles within ranges that reflect low-grade retinal inflammation similar 
to that observed in vitreous from patients with DR.89,296 Moreover, our reported induction 
of retinal leukostasis is comparable to that observed in rodent models of 
diabetes.266,297,298 The TNFα concentration we chose produced a significant increase in 
adherent retinal leukocytes with sufficient magnitude to test the addition of exogenous 
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EET and EDP to achieve statistical significance in this acute model, while at the same 
time maintaining relevance to the low-grade state of inflammation observed in DR.  
In our in vitro flow chamber experiments, we observed a partial inhibition of 
TNFα-induced leukocyte adherence compared to the complete mitigation of TNFα-
induced leukostasis we observed in the acute mouse model of retinal inflammation. A 
number of reasons could explain the differences between these results. First, we 
narrowed our survey of inflammation-related molecular targets to VCAM-1 and ICAM-1 
because they have been shown to mediate TNFα-induced leukostasis,298-300 and have 
precedence as EET-dependent targets.103,143,146,278 However, other targets are likely to 
contribute to leukocyte adherence in the in vivo setting, such as E-selectin or P-selectin, 
and their levels may also be EET- and/or EDP-dependent. Furthermore, though EET 
and EDP were locally administered, they may exert additional anti-inflammatory actions 
on the circulating leukocytes. Our in vitro experiments focused on the effects of EET 
and EDP on the retinal endothelial cells alone. Indeed, evidence from other studies 
suggests that these epoxides may also exert their effects on macrophages and 
monocytes.170-172,179,301,302 Hence, EET- and EDP-dependent effects on circulating cells 
may represent an important component of the in vivo pathogenesis that is absent in our 
in vitro studies. Lastly, our in vitro experiments were performed in human-derived 
microvascular endothelial cells, and our in vivo endpoints were performed in mice. The 
published IC50 value for AUDA related to inhibition of mouse sEH (18nM) is lower than 
that reported for the human variant (69nM).303 Therefore, AUDA is more potent for the 
mouse enzyme, and this may contribute to the improved efficacy observed in our mouse 
model. 
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This is the first study to directly compare the effects of EET and EDP on 
molecular and cellular events related to retinal vascular inflammation occurring in DR. 
While EDP has some bioactivities similar to those of EET, and in some cases 
demonstrating greater potencies such as in vasodilation,152 opposite biological 
outcomes have also been observed. For example, EDP has been reported to be anti-
angiogenic whereas EET is likely to be pro-angiogenic depending on the specific 
experimental context.148,164,281,283 In the present study we showed a similar potency for 
EET and EDP to reduce in vitro leukocyte adhesion and leukostasis in the mouse. This 
suggests that the mechanisms by which they exert their anti-inflammatory effects are 
similar. The mechanistic details of EET and EDP bioactivities remain undetermined. A 
specific receptor for epoxygenated fatty acids is yet to be identified, although they do 
signal through a number of pathways, including PPARs and GPCRs.142,143,304,305 The 
majority of evidence supporting EET anti-inflammatory activity points to signaling 
pathways that converge on the transcription factor NFκB. Node et al. originally showed 
that 11,12-EET exerted anti-inflammatory effects in bovine aortic endothelial cells by 
inhibiting IKK activity and IκBα degradation, thereby preventing NFκB translocation and 
initiation of pro-inflammatory mediator transcription.146 While subsequent studies 
validated this finding, they were all performed in macrovascular endothelial cell 
types.172,173 To our knowledge, this is the first study to show that NFκB activation is 
inhibited by 11,12-EET or 19,20-EDP in microvascular endothelial cells, but not via IκBα 
degradation.  
 Taken together, our data shows for the first time that 11,12-EET and 19,20-EDP, 
when combined with application of the sEH inhibitor AUDA, are similarly efficacious 
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against TNFα-induced leukocyte adherence in vitro and leukostasis in vivo. Both of 
these epoxides act in part by inhibiting the induction of VCAM-1 and ICAM-1. Based on 
the results of these studies, the addition of exogenous EET or EDP, along with their 
stabilization via sEH inhibitors, may represent a viable treatment strategy for DR. We 
believe that blocking retinal inflammation in the early stages of NPDR with EET and 
EDP therapy may prevent transition to PDR and its associated morbidities, including 
blindness.  
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CHAPTER V 
 
EFFECT OF EPOXIDES ON RETINAL ANGIOGENESIS 
 
From: Capozzi M.E., McCollum G.W., Penn J.S. (2014) The Role of Cytochrome P450 
Epoxygenases in Retinal Angiogenesis. Invest Ophthalmol Vis Sci. 10;55(7):4253-60. 
 
Overview 
 Angiogenesis is the sprouting of new blood vessels from pre-existing vessels and 
it occurs in both physiologic and pathologic settings. Persistent pathologic angiogenesis 
contributes to a number of diseases, including cancer and retinopathies. Abnormal 
retinal angiogenesis, also called neovascularization (NV), results from a vaso-
proliferative response to retinal hypoxia and occurs in retinopathy of prematurity (ROP), 
proliferative diabetic retinopathy (PDR), and age-related macular degeneration 
(AMD).306-308 These eye diseases account for the majority of vision loss in developed 
countries, creating an impetus to investigate the cellular and molecular mechanisms 
underlying retinal NV and develop effective therapies.  
While epoxide therapy for early diabetic retinopathy may be beneficial, as 
suggested from Chapter IV, the pro-angiogenic features of EETs may be 
contraindicated for late stages of the disease, such as PDR when neovascularization 
occurs. In fact, inhibition of EET production may be therapeutic for diseases 
characterized by retinal angiogenesis. Thus, the goal of the present study was to 
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develop a more complete understanding of EET in diabetic retinopathy by assessing its 
effect in late stages of the disease, which are characterized by pathologic NV. 
Vascular endothelial growth factor (VEGF), a 40kDa dimeric glycoprotein, is the 
primary mediator of angiogenesis in ocular diseases.309 Hypoxia is a potent stimulator of 
retinal VEGF, and ischemia-induced hypoxia is the major source of VEGF in ROP, and 
perhaps DR. The retinal Müller cells and astrocytes have been shown to produce the 
highest levels of VEGF of all retinal cell types,97 and therefore the present study will 
focus on the production of VEGF by these cells in vitro. Endothelial cells are the primary 
responders to VEGF, and thus will be used for assessment of angiogenic behaviors. 
COX, LOX and their products (prostaglandins, thromboxanes, and leukotrienes) 
have been well characterized in OIR.252,275,310,311 However, the contribution of AA-
derived CYP products to retinal angiogenesis was largely unknown. Therefore, the 
purpose of this study was to investigate the role of CYP2C epoxygenases and their EET 
products in retinal angiogenesis. Experimental evidence suggested that CYP2C 
enzymes are expressed in endothelium, are hypoxia-inducible, and their regio-
selectivities favor increased 11,12-EET over the other regioisomers. Therefore, we 
performed in vitro experiments to establish the effects of 11,12-EET to stimulate human 
retinal microvascular endothelial cell (HRMEC) proliferation and tubulogenesis. 
Furthermore, we assessed the effect of a general CYP inhibitor on induction of VEGF in 
human retinal glial cells and VEGF-induced angiogenic behaviors in HRMEC. We 
measured the expression of the human CYP2C homologs in primary human retinal cells 
exposed to hypoxia and determined the expression profile of CYP2C11 and CYP2C23 
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in OIR rats. Lastly, we tested the efficacy of the CYP inhibitor against pre-retinal NV in 
vivo, and whether its efficacy correlated with retinal VEGF levels in OIR rats. 
 
Results 
CYP2C23, but Not CYP2C11, is Increased in OIR Retinas 
In rat OIR, retinal VEGF peaks around two days post-oxygen exposure (14(2)).84 
Therefore we chose to investigate retinal CYP expression at this time because VEGF 
has previously been shown to crosstalk with the CYP pathway.149,160 Retinas collected 
on 14(2) from OIR showed a 2.4-fold (p<0.0001) increase in CYP2C23 mRNA relative 
to room air controls. Conversely, OIR had no effect on CYP2C11 expression (Figure 
23). 
 
 
Figure 23. CYP2C11 and CYP2C23 mRNA expression in rat OIR. Two days after removal 
from oxygen exposure (14(2)), CYP2C23 expression is significantly increased, while CYP2C11 
is unaffected in OIR compared to RA control (P16). Data are presented as mean ± SEM (n=6). 
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Hypoxia Induces CYP2C Expression in Human Retinal Astrocytes, but Not Human 
Müller Cells or HRMEC 
Cytochrome P450s are expressed in retinal endothelial cells, Müller cells and 
brain astrocytes.312-315 Therefore, we measured CYP expression in primary HRMEC, 
human Müller cells, and human retinal astrocytes (HRA). Exposure of HRA to hypoxia 
for 24 hours significantly induced human CYP2C8 (2.5-fold; p=0.0004) and CYP2C9 
(3.1-fold; p=0.0154; Figure 24C). However, the same hypoxic conditions did not induce 
CYP2C8 or CYP2C9 in either human Müller cells or HRMEC (Figure 24A and 24B, 
respectively). 
 
 
Figure 24. The effect of 24-hour hypoxic exposure of CYP-expressing retinal cell types on 
CYP2C8 and CYP2C9 expression. Hypoxia has not effect on CYP2C8 or CYP2C9 expression 
by (A) Müller cells or (B) HRMEC. However, hypoxia significantly elevates CYP2C8 and 
CYP2C9 expression by HRA. Data are presented as mean ± SEM (n=7-9). 
 
SKF-525A Reduces VEGF Production by HRA, but Not Müller Cells 
In response to hypoxia, Müller cells and retinal astrocytes have the greatest 
capacity to produce VEGF of all retinal cells.97 Therefore, VEGF production in hypoxic 
Müller cells and HRA was measured after treatment with SKF-525A for 24 hours 
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(Figure 25). Müller cells produced 3.6-fold more VEGF than astrocytes when exposed 
to hypoxia. Hypoxia-induced VEGF production was 7.1-fold in Müller cells and 11.5-fold 
in HRA. SKF-525A had no effect on Müller cell production of VEGF, however, it reduced 
HRA VEGF production by 26.8% (p=0.0097).  
 
Figure 25. The effect of SKF-525A on hypoxia-induced VEGF production in retinal glial 
cells. Human Müller cells (A) and HRA (B) were exposed to either normoxia (20.9% O2) or 
hypoxia (0.1% O2) in the presence or absence of SKF-525A (5.0µM) for 24 hours. The VEGF 
levels were measured in the culture medium and normalized to total protein. SKF-525A 
significantly decreased VEGF levels in hypoxic cultures of HRA, but not in hypoxic cultures of 
Müller cells. Data are presented as mean ± SEM (n=3-9). 
 
11,12-EET and SKF-525A Modulate HRMEC Proliferation 
As shown in Figure 26, treatment of HRMEC with increasing concentrations of 
11,12-EET stimulated proliferation in a dose-dependent manner. Proliferation was 
significantly increased by 1.5-fold (p=0.0051) and 1.6-fold (p=0.0004) at the 0.1µM and 
0.5µM doses of 11,12-EET, respectively. General CYP inhibition using SKF-525A 
significantly reduced VEGF-induced proliferation by 46% (p<0.0001) at the highest 
concentration (5.0µM). 
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Figure 26. The effect of 11,12-EET or SKF-525A on VEGF-induced proliferation of HRMEC. 
Treatment of HRMEC with 11,12-EET led to a dose-dependent increase in proliferation. 
Treatment with SKF-525A inhibited VEGF-induced proliferation at the highest concentration 
(5.0µM). Data are presented as mean ± SEM (n=9). 
 
Administration of Exogenous 11,12-EET, but Not SKF-525A, Affects HRMEC 
Tubulogenesis 
HRMEC were grown on Matrigel® in the presence of vehicle, 11,12-EET, VEGF 
vehicle, or VEGF plus SKF-525A. Tube formation was significantly induced by all doses 
of 11,12-EET (p=0.0135 at 0.05µM; p=0.0009 at 0.1µM; and p=0.0078 at 0.5µM). CYP 
inhibition by SKF-525A did not significantly inhibit VEGF-induced tube formation (Figure 
27). 
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Figure 27. The effect of 11,12-EET or SKF-525A on VEGF-induced tube formation in 
HRMEC. (A) Representative images from vehicle, 50ng/ml VEGF or 11,12-EET (0.5µM). The 
bar on each image represents 500µm. (B) HRMEC treatment with 11,12-EET significantly 
induced tube formation at all doses used. SKF-525A did not significantly inhibit VEGF-induced 
tube formation. Data are presented as mean ± SEM (n=6-12). 
 
SKF-525A Reduces Retinal NV in OIR 
Retinal NV was assessed in the rat model of OIR following intravitreal injection of 
vehicle or increasing concentrations of SKF-525A. 5.0µM SKF-525A significantly 
inhibited NV formation by 48% (p=0.0239). Representative retinal quadrants and SKF-
525A efficacy are shown in Figure 28A and 28B, respectively. 
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Figure 28. The effect of intravitreal injection of SKF-525A on OIR-induced pre-retinal NV. 
(A) Representative images from vehicle-treated and 5.0µM SKF-525A-treated OIR retinas. (B) 
Dose response of SKF-525A in OIR animals. Data are presented as mean ± SEM (n=8-12). 
 
SKF-525A Attenuates Retinal VEGF Production in OIR 
Animals were injected on 14(1) with vehicle or SKF-525A, and collected on 14(2), 
when retinal VEGF is known to peak in this model.84 Soluble VEGF protein was up-
regulated 5.6-fold in OIR retinas compared to room air controls. SKF-525A (5.0µM) 
significantly reduced VEGF induction in the OIR model by 34% (p=0.0229), as shown in 
Figure 29. 
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Figure 29. The effect of intravitreal injection of SKF-525A on VEGF production in rat OIR. 
Injection of 5.0µM SKF-525A significantly reduced retinal VEGF protein level at 14(2) compared 
to vehicle injection in rat OIR. Data are presented as mean ± SEM (n=18). 
 
Conclusions 
Hypoxia is a known inducer of CYP2C expression in bovine RMEC (BRMEC), 
and subsequently causes increased EET levels.159,312 Additionally, EETs are 
downstream effectors in the VEGF signaling pathway, promoting endothelial cell 
proliferation, tube formation, and migration.160,316 Therefore, EET production is likely to 
facilitate an enhanced retinal neovascular response. However, to our knowledge, 
reduction of EETs by CYP epoxygenase inhibition has never been tested as a 
therapeutic modality against retinal NV. 
In BRMEC, 11,12-EET is the only EET product significantly increased when cells 
are stimulated by hypoxia.312 In the present study, we showed that CYP2C23 is the 
primary OIR-induced CYP epoxygenase in the rat retina (Figure 23). Because 
CYP2C23 preferentially produces the 11,12-EET regioisomer,317 we chose to use 
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11,12-EET in our in vitro experiments. In this study, we show for the first time that 
11,12-EET induces pro-angiogenic cell behaviors in HRMEC (Figure 26 and 27). 
There are a number of possible cell types that produce cytochrome P450-derived 
EET products in the retina. Brain-derived astrocytes were the first source identified as 
hypoxia-stimulated producers of pro-angiogenic EETs.314,315 Additionally, BRMEC 
demonstrated hypoxia-induction of CYP2C mRNA expression over 24hrs.312 The retina 
also contains a large population of Müller glial cells that express CYP epoxygenases 
and the EET-metabolizing enzyme, soluble epoxide hydrolase, in a high abundance, yet 
their response to hypoxia has never been tested.132,313 In the present study, using 
primary human retinal cell types, we demonstrate that astrocytes are likely the 
predominant cell type contributing to hypoxia-induced CYP2C expression in the retina 
(Figures 23 and 24). 
Currently, no EET-specific receptor has been identified. However, data suggest 
that EETs likely bind and activate G-coupled protein receptors and/or peroxisome 
proliferator-activated receptors.143,157,318,319 The pro-angiogenic effects of EETs are 
mediated at least in part by activation of PI3K/Akt, ERK, and p38 MAPK.148,160,320 Yang 
and colleagues demonstrated that CYP activation in mouse primary lung endothelial 
cells led to phosphorylation of ERK1/2 and Akt and knockdown of the primary mouse 
CYP epoxygenase, Cyp2c44, inhibited VEGF-induced ERK and Akt phosphorylation 
and subsequent tube formation.160 Another study by Potente and colleagues showed 
that EET activates PI3K/Akt, inhibiting FOXO1 and FOXO3b and thereby 
downregulating p27Kip1, a cyclin-dependent kinase inhibitor. Subsequently Cyclin D1 
increases, inducing proliferation by promoting cell cycle progression.321 More recently, 
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GPR40, a medium/long chain fatty acid g-coupled protein receptor, was demonstrated 
as the mediator of EET-induced mitogenesis in kidney cell cultures.142 GPR40 deletion 
in the retina attenuated retinal angiogenesis in the Vldlr-/- mice,255 suggesting that 
perhaps EET pro-angiogenic activities occur through direct binding of this receptor. 
The general CYP epoxygenase inhibitor, SKF-525A, inhibits neuronal nitric oxide 
synthase (IC50 = 90mM) and blocks the potassium channel Kir6.1 (IC50 = 4.4mM).316,322 
Previous studies in models of hypertension have shown that at 50µM, SKF-525A 
inhibits CYP metabolism of AA by 90%.323 However at this concentration, we observed 
loss of cell viability in our experiments. We did not expect off-target effects of the drug 
because our experiments were performed using substantially lower doses. In our in vitro 
experiments, SKF-525A significantly inhibited VEGF-induced proliferation, however we 
did not observe any effect on VEGF-induced tube formation. Yet, in studies using 
HUVEC, the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) inhibited 
VEGF-induced tube formation.149 Additionally, Webler and colleagues demonstrated 
that VEGF stimulated CYP2C promoter activity and induced CYP2C8 expression.149 In 
the present study, we did not observe a VEGF-induced increase in CYP2C8 expression 
(data not shown). Therefore, VEGF induction of tubulogenesis likely occurs by CYP-
independent mechanisms in HRMEC. 
To our knowledge, this is the first demonstration that CYP inhibition can reduce 
neovascularization in an in vivo model of retinopathy. It has recently been shown that 
retinal Cyp2c expression is increased in mice exposed to hyperoxia.324 In addition, 
human CYP2C8 overexpression in OIR-exposed mice fed ω-3-enriched diet promoted 
retinal angiogenesis.324 Similarly, we show an up-regulation of CYP2C23 expression in 
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rats during the post-oxygen exposure period in OIR rats. Moreover, we show that 
inhibition of CYP activity, and presumably the consequent decrease in EET levels, 
reduces retinal NV. In rat OIR, retinal VEGF normally peaks at 14(2).84 In this study, 
OIR rats receiving intravitreal injections of SKF-525A showed reduced retinal VEGF 
levels at 14(2) (Figure 29), perhaps contributing to the inhibition of retinal NV observed 
at 14(6). Induction or exogenous addition of EETs has been shown to induce VEGF.325 
Inhibition of CYP2C9 by sulfaphenazole suppressed the hypoxia-induced transcriptional 
activity of the VEGF hypoxia response element in human umbilical arterial endothelial 
cells.326 In human dermal microvascular endothelial cells, 14,15-EET induced VEGF via 
a Src-STAT-3-dependent mechanism.325 However, in the retina, endothelial cells are 
not the major source of hypoxia-induced VEGF; Müller cells and astrocytes are the 
primary producers of VEGF of the retinal cell types.97 We found that inhibition of CYP 
epoxygenases in hypoxia-induced primary human Müller cells had no effect on VEGF 
production, however it significantly reduced production of VEGF by astrocytes (Figure 
25). This suggests that astrocytes are the primary cell type involved in SKF-525A 
inhibition of retinal VEGF, as shown in Figure 29. 
A previous study from Scicli’s group demonstrated the pro-angiogenic activity of 
the 20-HETE product derived from the CYP4A family.327 In this study, inhibitors of 
CYP4A demonstrated potent anti-angiogenic capacity in VEGF-induced HUVEC 
proliferation and VEGF-induced corneal vasculature growth.327 However, we believe 
that CYP epoxygenase inhibitors may provide better efficacy in retinal angiogenesis 
because they can inhibit both hypoxia-induced VEGF production by astrocytes and 
VEGF-induced angiogenic behaviors in retinal microvascular endothelial cells. 
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One limitation to the present study is that the focus was on AA-derived epoxides, 
and not DHA-derived epoxides. There is evidence that EDPs are angiostatic in 
cancer,164 and thus the presumed reduction of their levels via the use of SKF-525A may 
be counterproductive for pathological angiogenesis in the OIR model. However, the 
effects of EDP are controversial in ocular angiogenesis, where it has been most 
commonly studied. Lois Smith’s group has shown pro-angiogenic activity of 19,20-EDP 
in HRMEC, choroidal explants, and aortic ring assays,166,328,329 while Kip Connor’s 
group demonstrated an angiostatic effect of 19,20-EDP injections in the laser-induced 
choroidal neovascularization model.165 Furthermore, Ingrid Fleming’s group found that 
the diol product of 19,20-EDP, 19,20-DHDP, is involved in retinal angiogenesis during 
normal development, and not its epoxide substrate.132 Further work must be performed 
to understand these discrepancies. 
In this study, we have identified a novel contribution of CYP-derived 
epoxyeicosatrienoic acids to retinal angiogenesis. The CYP inhibitor SKF-525A reduced 
VEGF production by retinal astrocytes, VEGF-induced pro-angiogenic behavior in 
HRMEC, and NV area in the rat model of oxygen-induced retinopathy. Our findings 
suggest that EET-elevating therapies would likely promote the neovascularization in the 
late stages of DR. In fact, CYP-directed therapeutics may provide a promising target for 
inhibition of retinal NV, because it can partially inhibit both VEGF induction and 
downstream signaling of VEGF. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The work presented in this dissertation relates to the roles of CYP-derived 
epoxides in retinal vascular pathology secondary to diabetes. In Chapter I, I introduced 
the reader to pathology in diabetic retinopathy and the potential for elevating CYP-
derived epoxides as a potential therapeutic strategy for DR. Chapter II described the 
methodology used to complete the aims of the project. In Chapter III, I established 
Müller cell culture models utilizing diabetes-relevant stimuli that recapitulate early 
aspects of disease progression. The work in Chapter IV demonstrated a comparable 
anti-inflammatory effect of 11,12-EET and 19,20-EDP in TNFα-induced retinal vascular 
inflammation. Lastly, in Chapter V, I demonstrated that 11,12-EET induced 
angiogenesis in retinal microvascular endothelial cells, and thus inhibition of CYP 
activity reduced neovascularization in oxygen-induced retinopathy. 
Arguably the most significant finding from the study in Chapter III was that PA 
provides a more DR-relevant stimulus than D-glucose. Despite thorough investigation of 
high glucose as a diabetes-relevant stimulus, our studies in both Chapter III and 
Appendix A demonstrated that high glucose, which remains the gold standard for in 
vitro studies of DR, does not recapitulate diabetes-relevant endpoints, and instead fatty 
acid enriched culture conditions may be a better model to study the initiation of 
inflammation and angiogenesis by Müller cells. Notably, when cells were pretreated with 
D-glucose prior to stimulation with PA, expression of several targets of interest was 
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further amplified, suggesting that glucose predisposed the cells to greater sensitivity 
and/or responsivity. Müller cells were the focus of this work because fatty acid induction 
of pro-inflammatory and pro-angiogenic mediators appeared to be Müller cell-specific 
(Appendix A). Taken together, these data suggest that Müller cells may be more 
sensitive to systemic factors associated with diabetes. Being that Müller cell activation 
occurs early in animal models of diabetes,96 it is possible that their early activation may 
be an initial step in the development of chronic inflammation in DR. Future studies 
should be directed at how fatty acids specifically activate Müller cell production of pro-
inflammatory and pro-angiogenic mediators.  
Furthermore, while IL-1β and TNFα were potent stimulators of Müller cell 
inflammation, the analysis of PA-treated Müller cells showed the greatest overlap with 
targets identified by whole transcriptome analysis of STZ-treated animals. Transcripts in 
several pathways, including angiogenesis (Vegfa, Vegfb and Angptl4), WNT signaling 
(Sfrp1, Cldn1, Bmp4, Wisp1, and Wnt2b), and inflammation (Ltbp1, Islr, and Bmp4), 
were elevated in both our PA-treated Müller cell cultures as well as retinas of STZ-
treated animals.330 Additionally, the levels of these transcripts were sensitive to 
treatment with a p38 MAPK inhibitor, PHA666859, in STZ animals.330 MAPK signaling 
was identified as a significantly modulated pathway by both KEGG analysis (Figure 8) 
and Biocarta analysis (Figure 9) in our PA-treated Müller cell samples. Further 
evidence from retinal endothelium showed that ERK signaling contributes to retinal 
capillary dropout.331 Additionally, JNK phosphorylation is associated with neuronal 
apoptosis in retinas collected from STZ-induced diabetic rats and patients with DR.332,333 
Thus, modulation of MAPK signaling may be particularly efficacious for DR. Thus, one 
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impact of our PA-Müller cell model is that it provides a novel platform for high-
throughput analysis of therapeutic agents, before going to more expensive pre-clinical 
models.  
Co-treatment of palmitic acid and D-glucose, without any D-glucose 
pretreatment, did not yield an amplified inflammatory response. Additionally, pre-
treatment with D-glucose followed by treatment with D-glucose plus LA did not evoke 
the amplification observed following PA treatment (Appendix H). These data led us to 
hypothesize that glucose pre-treatment up-regulated components of PA-specific 
signaling pathways. One potential mechanism by which D-glucose could amplify PA-
induced inflammatory transcription is via induction of toll like receptor 4 (TLR4). In 
retinal microvascular endothelial cells, glucose elevated expression levels of TLR4.334 
Additionally, PA, but not any other unsaturated fatty acid, is a known ligand for TLR4, 
and its activation of the receptor leads to NFκB-dependent transcription and subsequent 
induction of inflammation.335,336 Our preliminary work did not show any effect of glucose 
on the expression of TLR4, however, this only demonstrates that levels remained 
unchanged and further work is necessary to determine whether: a) TLR4 receptors alter 
their localization for greater availability at the cell surface in response to glucose 
treatment or b) downstream signaling intermediates in the TLR4 pathway become 
increasingly elevated in response to combination treatments with glucose and PA. 
Another potential target for D-glucose amplification of PA responses is via increased 
HIF-1α stabilization and consequent transcription of angiogenic targets. As described in 
the study by Lois Smith’s group, alteration of glucose and fatty acid metabolism can 
cause hypoxia-independent HIF-1α stabilization,255 which could explain the increased 
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transcription of a variety of angiogenic factors in our whole transcriptome analysis. 
Identifying the mechanism by which D-glucose amplifies cells’ response to PA should 
remain a priority, as this may lead to the identification of several potential drug targets 
for treatment of early DR. 
Hyperlipidemia in the absence of diabetes does not yield DR-like pathology, so 
further understanding of metabolic and systemic interactions in the retina need to be 
pursued. Modeling a chronic, multifaceted disease like DR in vitro remains a challenge, 
but it is necessary to continue to develop better in vitro models for many reasons; a) 
PDR cannot be recapitulated in any known animal models. In rodent models, the 
disease pathology is mild and never progresses to late stages, so these models lack the 
potential to yield information about an important aspect of DR – the transition from 
NPDR to PDR; b) Use of human cells brings additional clinical relevance to in vivo 
findings. For example, IL-8 is one of the most elevated proteins found in the vitreous of 
diabetic patients, yet mice do not express IL-8. While rodents do express functional 
analogs, they might be regulated differently than IL-8. Therefore, human cells, which 
produce IL-8 may be important for understanding the mechanism of its induction as well 
its functional effects in DR pathogenesis; c) Cell culture models that recapitulate 
multiple disease processes allow for better mechanistic understanding of the disease. 
Use of human culture systems allows for assessment of efficacy for drugs targeting 
specific disease processes, as well as mechanistic steps in the pathologic cascade, 
which would allow for identification of novel therapeutic targets; and d) Cell culture 
models allow for high-throughput analysis in controlled treatment conditions. DR takes 
years to develop in humans, and months to develop in rodents. For these reasons, we 
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believe our culture model using human Müller cells and appropriate disease-relevant 
stimuli represents a useful tool for the DR research community. 
While further work must be performed, particularly in the in vivo setting using 
disease-relevant models, the work presented in Chapter III constitutes an important 
step in understanding the initial causes of diabetic retinopathy. Our results, which 
demonstrate that glucose elevation has no effect on important retinal cell types, suggest 
that we should reconsider our interpretations of the conclusions drawn from seminal 
clinical trials. Tight control of hyperglycemia was found to slow the progression of DR in 
the DCCT trials,13 and this has provided the basis for the mechanistic study of 
hyperglycemia-induced pathology. While it is likely that elevated circulating glucose can 
affect cellular signaling, studies in culture suggest that glucose is not a potent stimulus 
for a variety of endpoints observed in DR. Our lab and others have observed no effect 
of elevated glucose, outside of the effect caused by increased osmolarity of the growth 
medium, on cellular responses related to inflammation, basement membrane 
thickening, and angiogenesis in culture.237,256 Thus, it is worth considering the entire 
metabolic implication of altering HbA1c and how that might be translated into cell culture 
systems. For example, tight glucose control is currently maintained by altering systemic 
insulin levels. Elevating insulin systemically may have a direct impact on retinal disease. 
The full effect of insulin has not been thoroughly studied, however Tom Gardner’s group 
has demonstrated altered insulin receptor phosphorylation, and thus activation, in the 
retinas of both type 1 and type 2 models of diabetic complications.337,338 Furthermore, 
both increasing insulin levels in the eye via subconjunctival injections or lowering 
systemic glucose levels in an insulin-independent manner via SGLT2 inhibition had 
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equivalent effects on preventing photoreceptor cell death in an STZ rodent model.339 
This demonstrates that other diabetes-relevant metabolic factors besides glucose are 
abnormal in the diabetic state and likely contribute to diabetes-induced retinal 
dysfunction. Elevated circulating lipid is just one of many insults associated with altered 
insulin signaling. The majority of metabolic alterations have yet to be assessed as 
stimulators of DR-related pathology. Thus, determining the effect of non-glucose, 
diabetes-relevant stimuli should remain a high priority for understanding the onset of the 
disease. Identifying the initiating factors of DR would likely yield more efficacious 
therapeutic strategies, because they could be administered before severe structural 
damage occurs.  
Based on the results of our pathway analysis in Chapter III, I would expect 
epoxide-elevating therapies to be effective at inhibiting cytokine-induced inflammation. 
However, it remains unclear whether these epoxides could modulate PA- or DG/PA-
stimulated behaviors. PA-induced cytokine expression in hepatocytes correlated with 
sEH up-regulation and was down-regulated by CYP2J2 overexpression or 14,15-EET 
treatment,195,196,206 suggesting that PA-induced inflammation in Müller cells should also 
be susceptible to CYP-derived epoxide therapies. However, EETs have been shown to 
activate the MAPK pathway to exert pro-angiogenic activities,340 while p38 MAPK 
inhibition in diabetic animals decreased retinal COX-2 and vascular leukostasis.341 PA 
enriched MAPK signaling (Figures 8 and 9), suggesting that perhaps PA induction of 
the MAPK signaling pathway may be causally linked to expression of angiogenic 
factors, and EETs may exacerbate this effect. However, NFκB-dependent pathways 
were elevated as well, and this likely drives the inflammatory mediator expression 
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caused by PA. Thus, I would expect epoxides to be efficacious for inhibiting the 
induction of NFκB-regulated transcripts. As for cytokine auto-amplification, I would 
expect epoxides to reduce inflammatory mediator expression, because virtually all the 
enriched pathways (Figures 14 and 15) are regulated by CYP-derived epoxides. In 
preliminary studies (Figure 30), I have demonstrated that 11,12-EET or 19,20-EDP may 
be viable inhibitors of IL-1β-induced IL1β, IL6, or IL8 expression by human Müller cells. 
However, 11,12-EET and 19,20-EDP treatment significantly elevated TNFα. Further 
functional characterization of this response is required to understand the implications of 
these changes. For instance, Müller cells could be treated with IL-1β in the presence or 
absence of epoxide treatments, and the conditioned medium from these cells could be 
used to stimulate HRMEC outputs, such as leukocyte adhesion in the PPFC assay. As 
discussed in Chapter III, of all the stimuli analyzed by RNAseq, only TNFα significantly 
decreased the expression of a CYP epoxygenase enzyme. While my preliminary results 
suggest that EET and EDP can inhibit IL-1β-induced inflammatory mediator expression 
by Müller cells, I would expect an even greater efficacy of EET and EDP on TNFα 
induction of these targets (TNFα, IL1β, IL6, and IL8), because their exogenous addition 
would be overcoming an endogenous deficit.	
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Figure 30. The effect of 11,12-EET and 19,20-EDP on IL-1β-induced inflammatory 
mediator expression by Müller cells. Human Müller cells were treated concomitantly with IL-
1β (1ng/ml) and 11,12-EET (0.5µM) or 19,20-EDP (0.5µM). After 8 hours, RNA was isolated 
and expression was analyzed by qRT-PCR. (A) TNFα expression was significantly elevated 
while (B) IL1β, (C) IL6, and (D) IL8 expression was significantly decreased by these epoxides in 
this preliminary experiment. Bars represent mean ± SD (n=3). 
 
In Chapter IV, I demonstrated that EETs and EDPs are anti-inflammatory in 
cytokine-stimulated retinal microvasculature using both in vitro and in vivo models. 
Notably, this is the first study to compare EET and EDP head-to-head for their anti-
inflammatory actions in endothelial cells. My work established that, in human retinal 
microvascular endothelial cells, TNFα reduced EET levels in conditioned medium. 
Furthermore, TNFα-induced cell adhesion molecule expression and leukocyte adhesion 
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to treated monolayers was decreased when cultured with 11,12-EET or 19,20-EDP plus 
the sEH inhibitor, AUDA. These data were then translated into an in vivo acute retinal 
inflammation model, where co-treatment of 11,12-EET or 19,20-EDP with AUDA 
inhibited TNFα-induced retinal leukostasis.  
In addition to demonstrating that 11,12-EET and 19,20-EDP reduced vascular 
inflammation, I showed that treatment with the diol product of 19,20-EDP hydrolysis, 
19,20-DHDP, was pro-inflammatory. This is particularly interesting considering the 
results reported by Ingrid Fleming’s group in the retina, in which 19,20-DHDP, and not 
the parent substrate, drove physiologic angiogenesis.132 No other functions of this diol 
have been reported outside of the retina. Additional studies of the 19,20-EDP 
demonstrated opposing results as to whether it possesses angiogenic or angiostatic 
activities in retinal and choroidal neovascularization.165,166,328,329 Hence, determining 
whether 19,20-EDP is pro-angiogenic, or if this is in fact a characteristic of the diol 
product, remains particularly important for the development of epoxide-elevating 
therapies. 11,12-EET, while equally anti-inflammatory to 19,20-EDP, unequivocally 
exerts a pro-angiogenic effect in the retina, based on our studies in Chapter V, and this 
is supported from additional evidence in the retina.166,283 Thus, if EDP is anti-angiogenic, 
promoting its levels would be the ideal therapeutic strategy for epoxide-directed 
therapies in DR, because unlike EET, its positive effects would not be contraindicated in 
late stages of the disease characterized by neovascularization. This could be 
accomplished by either administration of exogenous 19,20-EDP or increased ω-3 fatty 
acid consumption, either of which could be combined with a sEH inhibitor. 
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Another approach to harnessing the anti-inflammatory capacity of epoxides is to 
understand the downstream signaling mechanisms involved. I observed in Chapter IV 
that EET and EDP exerted similar anti-inflammatory effects on retinal microvascular 
endothelial cells, yet several studies have shown an opposite effect of EET and EDP in 
angiogenesis. This suggests that perhaps the two epoxide classes are working through 
separate pathways, and potentially different receptors, for their inflammatory and 
angiogenic behaviors. I began to query the GPR40 receptor as a potential target of 
epoxide signaling in retinal endothelial cells, because it was recently demonstrated to 
mediate the mitogenic effects of EET on kidney cells in culture.142 GPR40 is a 7-
transmembrane domain, medium/long chain fatty acid receptor that is highly expressed 
in pancreas and brain.342 While only the mitogenic effect of EET activity has been 
attributed to GPR40 agonism, several studies show similar bioactivities between 
epoxides and GPR40 agonism. Most relevant to our studies, GPR40 agonism inhibited 
inflammatory mediator production by keratinocytes and beta cells.343,344 AA and DHA, 
acting as ligands for GPR40, have shown opposing effects on mitogenesis; AA induced 
wound healing via GPR40 activation of mesenchymal stem cells,345 while DHA and the 
GPR40 agonist, TAK-875, reduced melanoma size in a rodent subcutaneous xenograft 
model of human melanoma.346 Notably, deletion of GPR40 (Ffar1) reduced retinal 
angiogenesis in the deep vascular plexus of Vldlr-/- mice.255 These data suggest that 
perhaps GPR40-mediated epoxide signaling in HRMEC regulates inflammation and/or 
angiogenesis. I performed preliminary studies to characterize the potential role of 
GRP40 in retinal angiogenesis and HRMEC inflammation. While I did not observe an 
effect of GPR40 in the mouse OIR model (Figure 31), I did observe a potential role for 
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GPR40 in 11,12-EET’s inhibition of TNFα-induced VCAM1 expression (Figure 32), 
suggesting that the anti-inflammatory, but not pro-angiogenic activities of EET might be 
mediated via GPR40 activation. However, preliminary studies utilizing GPR40 agonists 
have not demonstrated any anti-inflammatory activities against TNFα-stimulated 
HRMEC cultures (Appendix G). Notably, GPR40 agonism was clinically tested for 
glycemic control in Japanese type 2 diabetics, and was found to be efficacious and well 
tolerated.347 Taken together, these data suggest that future work should focus on 
understanding epoxide signaling in HRMEC, potentially through the GPR40 pathway, as 
a way to harness the positive attributes of the epoxide activities for DR. 
 
 
Figure 31. The effect of GPR40 antagonism on pre-retinal neovascularization in mouse 
OIR model. Mice received intravitreal injection of either vehicle (0.1% DMSO), or two doses of 
GW1100, a GPR40 inhibitor, upon removal from hyperoxic exposure. Neovascularization was 
measured in retinal flat-mounts 5 days post-removal from oxygen exposure. No effect of GPR40 
inhibition was observed (n=4-5).  
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Figure 32. The effect of the GPR40 inhibitor, GW1100, on 11,12-EET + AUDA inhibition of 
TNFα-induced VCAM1 expression. HRMEC were treated with vehicle, TNF-α vehicle 
(50ng/ml), TNFα + 11,12-EET (0.5µM) + AUDA (10µM), or TNFα + 11,12-EET (0.5µM) + AUDA 
(10µM) + GW1100 (1.0µM) for 2hrs, and VCAM1 expression was analyzed by qRT-PCR. As 
anticipated, 11,12-EET + AUDA inhibited TNFα-induced VCAM1, as shown in Figure 18. 
Addition of a GPR40 inhibitor, GW1100, partially attenuated this inhibition (n=6). 
 
Currently, there are several anti-inflammatory options available for clinical use, 
including corticosteroids, NSAIDs, TNFα inhibitors, and anti-VEGF therapies. Like the 
epoxides, corticosteroids have a broad range of targets and are capable of reducing 
inflammation, vascular leakage and VEGF transcription, but they are short acting and 
yield unwanted complication including elevation of IOP and cataract.348 While COX-2 
inhibition via low oral doses of aspirin uses a more desirable route of administration and 
is widely known to be safe, clinical trials assessing its potential use for DR have not 
demonstrated any benefits.125,126 Etanercept, which inhibits TNFα, is approved for the 
treatment of psoriasis, and due to TNFα’s proven role in DR pathogenesis would be a 
likely candidate for anti-inflammatory treatment. However, in preliminary reports of its 
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use in patients with DME, no statistically significant improvements were observed.349 
This may be due, in part, to the large number of inflammatory cytokines elevated during 
DR, with some functional redundancy to TNFα, such as IL-1β. Thus, there remains a 
need to develop novel anti-inflammatory agents that are safe, efficacious, and more 
easily delivered.  
Based on the data from Chapter IV and the preliminary data in Figure 30, 
epoxide-elevating therapies may be superior anti-inflammatory agents compared to the 
current strategies considered for clinical use. First, epoxide levels were decreased in 
retinal endothelial cells stimulated with TNFα (Figure 16), and while total retinal epoxide 
levels were unaffected, the ratio of diols to epoxides was decreased in response to 
acute inflammation (Appendix F). This is consistent with the observation of decreased 
epoxides in the vitreous of patients with diabetic retinopathy.89 These data suggest that 
enzymes controlling epoxide levels are dysregulated in DR. Thus, epoxide elevation 
strategies would be tolerated because treatments would be designed to return epoxides 
to endogenous levels.  Additionally, epoxide therapies appear to exert their activities 
against both upstream production of inflammatory mediators and downstream response 
to these inflammatory mediators. Hence, epoxide therapy could exert influence at 
multiple steps along the DR pathogenic cascade, potentially providing greater overall 
efficacy. Lastly, epoxides regulate multiple inflammatory targets, which provide an 
advantage over mono-therapy strategies.  
An important and logical next step for this project is to demonstrate whether 
diabetes alters the levels of CYP-derived epoxides in the retina. A goal of the present 
work was to identify the effects of various diabetes-relevant stimuli on the levels of 
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epoxides, because, as reviewed in Chapter I, several studies have shown down-
regulation of CYP enzymes or up-regulation of sEH in response to diabetes-relevant 
conditions in other cell types or tissues. We began to characterize these changes in our 
models (Figures 16, 23, 24, and Appendix C and F). However, more appropriate 
models need to be utilized to assess whether the CYP/sEH enzymes are impaired in the 
diabetic retina. Future studies should use a complement of models to understand the 
role of systemic diabetes on retinal epoxide levels, since several factors are known to 
modulate these enzymes and the metabolic profile will likely vary between models. I 
recommend comparing studies of CYP-derived epoxides from vitreous or aqueous 
samples of diabetic retinopathy patients to a variety of animal models, including STZ-
induced diabetes models, diet-induced obesity or other genetic type 2 models, and OIR 
models. Retinal epoxide levels should be measured instead of CYP enzyme levels in 
these studies, because the full complement of CYP epoxygenase enzymes is unknown. 
Furthermore, CYPs possessing epoxygenase activity continue to be identified. While 
members of the CYP2C and CYP2J family are the most thoroughly studied, several 
other CYP enzymes exhibit epoxygenase activity.129 In fact, in Müller cell whole 
transcriptome analysis, the only epoxygenase that was significantly altered by any 
stimulus was CYP2S1, which until recently was considered an orphan P450.129 Thus, 
before analyzing expression of specific CYP enzymes, a systematic study of all CYP 
epoxygenases in the human retina needs to be performed. 
Ultimately, our results demonstrate proof of concept for retinal anti-inflammatory 
activity of CYP-derived epoxides. Therefore, the next studies in the lab should focus on 
long-term treatment with EET and EDP analogs or sEH inhibitor in systemic diabetes 
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models. Water-soluble epoxide analogs have been developed and utilized in vivo for 
systemic treatment of hypertension and nephrotoxicity.350,351 Furthermore, the sEH 
inhibitor, GSK2256294, which has been used in early phase clinical trials, shows 
favorable pharmacokinetics profiles when delivered to rodents by oral 
administration.352,353 Thus, the ability to systemically administer these therapeutics is 
particularly advantageous, because current DR treatment strategies utilize a more 
invasive route of administration, intravitreal delivery. Furthermore, in rodents, the globe 
does not tolerate repeat injections, thereby posing problems for dosing and 
pharmacokinetic optimization in preclinical, long-term disease models. I hypothesize 
that epoxide-directed therapies would be efficacious against early non-proliferative DR. I 
expect that these therapies will have several beneficial effects related to their direct anti-
inflammatory activities, indirect effects mediated by the resulting inhibition of cytokine 
production and leukostasis (i.e. reduced vascular permeability), and additional biological 
activities (i.e. vaso-dilation). However, any beneficial effects should be interpreted with 
caution because no experimental diabetes models have been shown to progress to 
PDR. Hence, it is unlikely that the pro-angiogenic capacity of epoxide elevation can be 
analyzed in diabetic animals, and this is important to gauge whether epoxides promote 
transition to PDR. Furthermore, this potential negative impact of epoxide elevation in the 
retina should be a consideration for the development of sEH inhibitors in the clinic. For 
instance, clinical trials have been performed in pre-diabetic patients to assess the effect 
of systemic sEH inhibition on hypertension (Arete Therapeutics; NLM identifier: 
NCT00847899), and this treatment would presumably elevate intraocular epoxide 
levels. This patient population may be susceptible to DR and subsequent 
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neovascularization, and therefore retinal outcomes should be considered when 
designing these clinical trials. 
In summary, I have defined novel disease-relevant Müller cell culture conditions, 
demonstrated the comparative anti-inflammatory capacity of EET and EDP in the retina, 
and confirmed the pro-angiogenic activity of EET in retinal neovascularization. Taken 
together, this work comprises an important step in our understanding of DR 
pathogenesis and the potential development of CYP epoxide-elevating therapeutic 
strategies for early, but not late, DR.  
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Appendix A 
 
 
 
The effect of oleic acid, linoleic acid, and elevated glucose on the production of VEGF, IL-
6, and IL-8 by human retinal glial cells and blood-retina barrier cells. Human Müller cells, 
retinal microvascular endothelial cells, ARPE-19, and retinal astrocytes were treated with 1) 
BSA control (100µg/ml), 2) BSA-bound oleic acid (60µM), 3) BSA-bound linoleic acid (60µM), 4) 
Normal glucose (5.5mM), 5) L-glucose (5.5mM D-Glucose + 20mM L-glucose); osmotic control, 
and 6) D-glucose (25.5mM) for 36 hours. Secreted VEGF, IL-6, and IL-8 was assayed in the 
culture medium by ELISA. *p<0.05 compared to BSA control, #p<0.05 compared to normal 
glucose control. Bars represent average ± SEM (n=9). 
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Appendix B 
 
 
 
Comparison of RNAseq differences to PCR validation expression assays for (A) IL8 and 
(B) PTGS2 expression. Using human Müller cells derived from 3 individual donors, we 
recapitulated the differential expression observed by RNAseq. The treatment groups are as 
follows: LG/BSA, 24 hours L-glucose, 24 hours L-glucose + BSA; LG/PA, 24 hours L-glucose, 
24 hours L-glucose + PA; DG/BSA, 24 hours D-glucose, 24 hours D-glucose + BSA; DG/PA, 24 
hours D-glucose, 24 hours D-glucose + PA. RNAseq bars represent mean value of log2fold 
change from RNAseq (n=2); qRT-PCR bars represent mean ± SEM (n=9).  
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Appendix C 
 
 
 
The effect of PA on EET/EDP levels in Müller cell cultured medium. Müller cells were 
treated with either BSA (vehicle; 100mg/ml) or BSA-conjugated PA (250µM) for 24 hours. AA 
(10µM) or DHA (10µM) was added for the last 3 hours of treatment. PA had no effect on 
epoxide levels in this preliminary experiment (n=3).  
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Appendix D 
 
 
The effect of inflammatory mediators on leukocyte adhesion behaviors in HRMEC. (A) 
HRMEC were treated with 1ng/ml of TNFα, IL-1β, IL-6, or IL-8 for 2 hours and cell adhesion 
molecule expression was assessed by qRT-PCR. VCAM-1 and ICAM-1 were elevated by TNFα 
and IL-1β, but not IL-6 or IL-8. (B) HRMEC monolayers were treated with 1ng/ml of TNFα, IL-1β, 
IL-6, or IL-8 for 4 hours, PBMC were flowed over the monolayers in a parallel plate flow 
chamber, and leukocyte adhesion was counted. TNFα was the only mediator that significantly 
induced leukocyte adhesion to treated monolayers. Bars represent mean ± SEM (A: n=9; B: 
n=4-6). 
  
Ve
hic
le
TN
Fα
IL-
1β IL-
6
IL-
8
0.0
0.5
1.0
1.5 VCAM-1
R
el
at
iv
e 
VC
A
M
1 
Ex
pr
es
si
on
 v
s.
 1
8S
Ve
hic
le
TN
Fα
IL-
1β IL-
6
IL-
8
0.0
0.5
1.0
1.5
R
el
at
iv
e 
IC
A
M
1 
ex
pr
es
si
on
 v
s.
 1
8S ICAM-1
Ve
hic
le
TN
Fα
IL-
1β IL-
6
IL-
8
0
20
40
60
80
100
A
dh
er
en
t L
eu
ko
cy
te
s/
m
m
2
A 
B 
	 122 
Appendix E 
 
A 
 
B 
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The effect of AUDA alone on TNFα-induced inflammation. (A) Cells were treated as 
described for Figure 18, but in the absence of exogenous epoxides. sEH inhibition with AUDA 
(10µM) has no effect on TNFα-induced VCAM-1 and ICAM-1 protein levels in HRMEC. Bars 
represent mean ± SD (n=4). (B) Cells were treated as described for Figure 21, but in the 
absence of exogenous epoxides. sEH inhibition with AUDA (10µM) had no effect on TNFα-
induced NFκB activity in HRMEC. Bar represent mean ± SEM (n=8). (C) Animals were treated 
as described for Figure 22, but in the absence of exogenous epoxides. sEH inhibition with 
AUDA (10µM) had no effect on TNFα-induced retinal leukostasis (TNFα: n=5; AUDA: n=8).  
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Appendix F 
 
A        
 
B        
 
 
The effect of TNFα intravitreal injection on (A) retinal epoxide levels and (B) EET:DHET 
ratio. (A) Animals received intravitreal injection of TNFα (50ng/ml) and retinas were collected 
6hrs post-injection. Four retinas were pooled for each measurement. None of the CYP epoxide 
products were significantly altered in the retina. Bars represent mean ± SEM (n=6-9). (B) 
Retinas were treated as described for (A). Retinal DHETs were only detectable from 3 of the 
samples. For these samples, the totals EETs were compared to the total amount of their diol 
products. TNFα treatment significantly decreased EET:DHET, suggesting an increased activity 
of sEH. Bars represent mean ± SD (n=3).  
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Appendix G 
A
 
B 
 
 
The effect of GPR40 on HRMEC cell adhesion molecule expression. HRMEC were treated 
with either a GPR40 inhibitor, GW1100, TNFα, or TNFα plus one of two GPR40 agonists; 
GW9508 or TAK-875. (A) GPR40 antagonism had no effect on basal VCAM1 expression and 
GPR40 agonism did not inhibit TNFα-induced VCAM1 expression. (B) A dose response of 
GPR40 agonism with TAK-875 did not inhibit TNFα-induced VCAM1 expression. However, 
TAK-875 at the highest dose (100nM) stimulated ICAM1 expression. Bars represent mean ± SD 
(n=3). 
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Appendix H 
 
 
The effect of D-glucose pre-treatment on LA and PA-stimulated IL8 expression in human 
Müller cells. Müller cells were pre-treated with either L-glucose or D-glucose as described for 
the studies in Chapter III. Cells were then treated with the same stimulus (L-glucose or D-
glucose) plus either LA (60µM) or PA (250µM). These different doses were identified to be 
optimal stimulators of Müller cell inflammation for each fatty acid. PA, but not LA, further 
stimulated IL8 expression when pre-treated with D-glucose. Bars represent mean ± SD (n=3).
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